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Abstract 
 
Botulinum neurotoxin type A (BoNT/A) is one of the most potent toxins known and a potential 
biological threat. At the same time, it is among the most widely used therapeutic proteins 
used yearly by millions of people, especially for cosmetic purposes. Currently, its clinical use 
for treatment of certain types of pain is increasing, and its long-term effectiveness represents 
a special clinical value. Efficacy of BoNT/A in different types of pain has been found in 
numerous clinical trials and case reports, as well as in animal pain models. However, sites 
and mechanisms of BoNT/A actions involved in nociception are a matter of controversy. In 
analogy with well known neuroparalytic effects in peripheral cholinergic synapses, presently 
dominant opinion is that BoNT/A exerts pain reduction by inhibiting peripheral 
neurotransmitter/inflammatory mediator release from sensory nerves. On the other hand, 
growing number of behavioral and immunohistochemical studies demonstrated the 
requirement of axonal transport for BoNT/A’s antinociceptive action. In addition, toxin’s 
enzymatic activity in central sensory regions was clearly identified after its peripheral 
application. Apart from general pharmacology, this review summarizes the clinical and 
experimental evidence for BoNT/A antinociceptive activity and compares the data in favor of 
peripheral versus central site and mechanism of action. Based on literature review and 
published results from our laboratory we propose that the hypothesis of peripheral site of 
BoNT/A action is not sufficient to explain the experimental data collected up to now.  
 
 
Keywords: botulinum toxin type A; pain; axonal transport; sensory nervous system, 
synaptosomal-associated protein of 25 kDa 
 
Highlights: 
- BoNT/A is therapeutically useful in certain chronic pain conditions and migraine 
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- Dominant hypotheses assume its exclusive activity on peripheral nerve endings 
- However, BoNT/A axonal transport from periphery to CNS has been discovered 
- Recent research revealed that BoNT/A action on pain involves central action 
 
Abbreviations: 
BoNT/A, botulinum toxin type A; LC, light chain; SV2; synaptic vesicle protein 2; SNAP-25, 
Synaptosomal-Associated Protein of 25 kDa; SNARE, Soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor;  VAMP, vesicle-associated membrane protein; TeNT; 
tetanus toxin; GABA (y-aminobutyric acid; CGRP, calcitonin gene-related peptide; TRPV1, 
transient receptor potential vanilloid 1; PC-12, pheochromocytoma-12 
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1. INTRODUCTION 
 
In the last 15-20 years, use of botulinum toxin type A (BoNT/A) has expanded to cover 
different painful disorders. Initially it was reported that BoNT/A relieves pain associated with 
spasticity and cervical dystonia. Based on the discovery that BoNT/A may reduce the 
frequency of chronic migraine attacks and associated pain, its effectiveness has been 
clinically investigated in chronic migraine treatment (Dodick et al., 2010) and approved in 
USA in 2010. Additionally, BoNT/A beneficial effect has been reported in off-label studies in 
many clinical disorders, such as lower back pain, myofascial pain, trigeminal neuropathy, 
temporomandibular joint disorders, osteoarthritis, etc. (Section 4. 1. 2). In different clinical 
conditions, reduction of pain hypersensitivity lasting for several months after single 
application makes BoNT/A a unique antinociceptive drug. Although the effect of BoNT/A on 
peripheral cholinergic synapses in different muscular and autonomous disorders has been 
well characterized, the mechanism of BoNT/A action on pain is still unknown. In this review 
we will focus on the most relevant findings and current hypotheses on the mechanism of 
BoNT/A antinociceptive actions. Though the BoNT/A action on pain is still dominantly 
believed to be of peripheral origin (Aoki and Francis, 2011; Francisco et al., 2012; Wheeler 
and Smith, 2013), novel experiments demonstrated that BoNT/A is axonally transported to 
central sensory regions, and proposed that its antinociceptive action is centrally mediated 
(Bach-Rojecky et al., 2009; Drinovac et al., 2013; Marinelli et al., 2012; Matak et al., 2011). 
These new findings raise many additional questions on the mechanism of BoNT/A 
antinociceptive action, and possibly some other CNS effects, which need to be answered.  
 
 
2. BOTULINUM TOXIN: FROM THE MOST POTENT POISON TO CLINICAL USE 
 
7 
 
Botulinum toxin (BoNT) is produced by Gram-positive rod-shaped anaerobic bacterium 
Clostridium botulinum and few similar Clostridia (C. butyricum, C. baratii and C. 
argentinense) (Popoff and Bouvet, 2005). BoNT is a protein complex consisting of neurotoxic 
part (which proteolytically targets synaptic proteins involved in vesicular neurotransmitter 
release) and auxiliary proteins (in details explained in Section 3). There are seven well 
known antigenically distinct BoNT serotypes (A-G), with the most recent serotype H being 
reported and currently characterized (Dover et al. 2013; Barash and Arnon, 2013). 
Additionally, six serotypes may have additional subtypes (Dover et al., 2009; Kalb et al., 
2011).  
BoNT/A is one of the most potent toxins known. Estimated intravenous median lethal dose in 
humans is only 1 ng/kg or 70 ng/70 kg person (Gill, 1982). One gram of inhaled toxin could 
kill more than 1 million people, making BoNT a potential biological threat (Arnon et al., 2001; 
Bigalke and Rummel, 2005; Franz et al., 1997; Gill, 1982).  
 
2. 1 Botulism  
 
Systemic BoNT intoxication induces botulism, a neuroparalytic disease with a low incidence, 
but fatal outcome in 5-10% of cases (WHO 2013). Main features of botulism, caused 
primarily by inhibition of peripheral cholinergic transmission, are long-term flaccid paralysis of 
skeletal muscles, and impairment of gastrointestinal and autonomic nervous system. Effects 
on sensory system have also been reported occasionally (Goode and Shearn, 1982; 
Kuruoğlu et al., 1996; Martínez-Castrillo et al., 1991). Symptoms of botulism usually appear 
within 12 to 36 hours following the exposure to toxin, but sometimes with a delay of up to 8 
days. First symptoms are relatively mild (weakness and vertigo, dry mouth and difficulty in 
swallowing and speaking) leading to progressive paralysis of skeletal muscles, ending in 
respiratory failure in more severe cases. Immediate treatment consists of early administration 
of antitoxin and intensive respiratory support (WHO 2013). In humans, botulism is mostly 
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caused by BoNT serotypes A, B, E, and rarely F (Sobel et al., 2005). Known types of 
botulism are: 
1. Food-borne botulism (intoxication with toxin-contaminated food), characterized accurately 
for the first time by the early 19th century German physician Justinus Kerner, who described 
symptoms of food poisonings caused by ingestion of contaminated smoked sausages 
(botulus - lat. sausage) (Erbguth, 2008). It is the most common form of BoNT poisoning 
associated with different types of mainly home-made food preserved in anaerobic conditions. 
Spores of Clostridium botulinum are heat-resistant, while the toxin itself is destroyed by 
boiling (WHO 2013).  
2. Inhalational botulism is very rare, and can occur due to exposure during industrial 
production of toxin. Theoretically, it might become a very serious threat if the toxin is used as 
a biological weapon (Arnon et al., 2001).  
3. Iatrogenic botulism has been reported after cosmetic use of high-dose of illegal BoNT/A 
preparation, and in pediatric patients treated with high dose of BoNT/A for spasticity 
(Chertow et al., 2006; Crowner et al., 2007). 
In addition to poisoning with BoNT, botulism can also be caused by anaerobic toxo-infection 
with C. botulinum endospores, which germinate and produce the toxin inside the body.  
4. “Infant botulism”, is associated with anaerobic conditions adequate for ingested spore 
germination in the intestinal tract of infants under 6 months of age (Brook, 2007). Up to 20 % 
of the honey specimens from different countries may contain spores of botulinum toxin 
(Nakano et al., 1990). Parents and caregivers are warned not to feed infants before the age 
of 1 year with honey (WHO 2013).  
5. Adult intestinal toxemia botulism can occur if the normal gut flora has been altered as a 
result of surgical procedures or antibiotic therapy (WHO 2013). 
6. Wound botulism occurs due to wound infection with C. botulinum. It has recently been 
reported in intravenous drug abusers (Sobel, 2005; Wenham, 2008).  
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2. 2 BoNT/A as a useful drug 
 
Ability to purify botulinum toxins (serotypes A and B) and use them locally in very low doses, 
as well as their long term activity (lasting up to several months), have been the basis of their 
clinical use in various neuromuscular and autonomous disorders. The idea of using small 
doses of BoNT for therapeutic purposes was proposed for the first time by J. Kerner in 1822 
(Kerner, 1822; reviewed by Erbguth, 2008). C. botulinum was characterized in 1897, and 
different BoNT serotypes were identified and purified in the 20th century (Erbguth, 2008). In 
the late 1960s and 1970s, based on preclinical experiments with monkeys, injections of small 
doses of purified BoNT/A into the lateral or medial rectus muscle have been initially used in 
the treatment of strabismus (Scott et al., 1973; Scott, 1980). BoNT/A has been approved for 
the use in strabismus in 1989, and later in other types of muscular hyperactivity disorders like 
blepharospasm, hemifacial spasm, focal dystonia and upper limb spasticity (reviewed by 
Barnes 2003; Thengannat et al., 2012). Apart from movement disorders, BoNT/A has been 
used for treatment of autonomous system disorders (approved in primary axillar 
hyperhidrosis and urinary incontinence caused by neurogenic detrusor overactivity) 
(Dressler, 2013; Naumann et al., 2013; Seth et al., 2013), and in non-muscular pain 
conditions (reviewed in detail in Section 4). Cosmetic use of BoNT/A for wrinkle correction 
was approved in USA in 2002. Today, due to its applications for medical and cosmetic 
purposes, BoNT/A is one of the most commonly used therapeutic proteins. Botulinum toxin’s 
growing market is estimated to reach the profit/the sales of $2.9 by 2018 (Chapman, 2012). 
Presently, BoNT/A is produced by over 20 manufacturers in US, Europe, and other parts of 
the world (Truong et al., 2009). Potency units for each of the BoNT products are specific, and 
cannot be compared or converted between different products. Therefore, Food and Drug 
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Administration (FDA) approved new names for different BoNT products registered in USA 
(FDA 2009; FDA 2013):  
- Botox (Botulinum toxin type A); new name: onabotulinumtoxinA 
- Botox Cosmetic (Botulinum toxin type A); new name: onabotulinumtoxinA 
- Dysport (Botulinum toxin type A); new name: abobotulinumtoxinA 
- Xeomin (Botulinum toxin type A); new name: incobotulinumtoxinA 
- Myobloc (Botulinum toxin type B); new name: rimabotulinumtoxinB 
 
 
3. MECHANISM AND MOLECULAR TARGETS OF BONT/A ACTION 
 
3. 1. Pharmacokinetics  
3. 1. 1 Structure of BoNT/A complex 
BoNT/A molecular complex of 900 kDa consists of toxic part (150 kDa) and auxiliary proteins 
(750 kDa). The toxic part consists of two polypeptide chains connected with disulphide 
bridge. The larger, heavy chain (100kDa) contains a carboxy terminal membrane acceptor-
binding domain (HC) and a translocation domain at the N terminal (HN), which mediate the 
toxin binding to nerve terminals and translocation of light chain into the cytosol (Gu and Jin, 
2013; Lee et al., 2013).  
50 kDa light chain (LC) enters the cytosol and prevents neurotransmitter release by 
enzymatic cleavage of Synaptosomal-associated protein of 25 kDa (SNAP-25) (Section 3. 2). 
Auxiliary proteins containing haemaglutinins and non-haemaglutinins participate in the 
stabilization of the BoNT/A complex and preservation in extracellular space and throughout 
the gastrointestinal tract (Chen et al., 1998; Gu and Jin, 2013; Lee et al., 2013).  
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Figure 1 
 
3.1.2 Absorption and distribution  
In the gut, BoNT/A 150 kDa neurotoxin is transcytosed from lumen of small intestine across 
the epithelial lining. Similarly, inhaled BoNT/A may penetrate the bloodstream across lung 
alveolar epithelium. BoNT/A is transported from apical to basolateral surface of epithelial 
cells, from where it enters the bloodstream or lymph vessels. It then reaches extracellular 
fluid in various tissues and targets peripheral nerve endings (Simpson et al., 2013). 
Differences in estimated human LD50 doses of BoNT/A delivered orally and intravenously 
(70 µg vs. 0. 09-0. 15 µg in 70 kg human, respectively) (Sobel et al., 2005) suggest that only 
a small fraction of orally ingested active BoNT/A can cross from the gastrointestinal tract into 
the systemic bloodstream. This is due to the inactivation of a large portion of orally-ingested 
BoNT/A by the low pH HCl in the stomach or degradation by digestion enzymes (Sugii et al., 
1977). Dose necessary for inhalational poisoning (0.8-0.9 µg) (Sobel et al., 2005) suggests 
higher rate of bloodstream penetration than after oral administration. Auxiliary proteins are 
not necessary for 150 kDa toxin absorption from small intestine and lungs (Maksymowych et 
al., 1999; Al-Saleem et al., 2012). 
Experimental assessment of systemic pharmacokinetic of intravenously-administered 
BoNT/A was performed in rodents (Ravichandran et al., 2006). The elimination half-life of 
active, non-metabolized toxin was around 4 hours. Majority of the toxin was unbound to 
plasma proteins (85-95 %).  
The time course of BoNT/A poisoning was studied using intravenous (i.v.) administration of 
polyclonal neutralizing antibody (BoNT/A antitoxin) at different time points following high-
dose toxin i.v. delivery. Antitoxin administered 10 min after BoNT/A only partially prolonged 
the animal survival. After 20 min it was almost completely unable to prevent the symptoms of 
BoNT/A poisoning in experimental animals (Ravichandran et al., 2006). This signifies that the 
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process of BoNT/A distribution and entrance into the tissue target peripheral nerve endings 
occurred within minutes.  
Dependently on the volume and dose, therapeutically used BoNT/A may spread from the 
injection site, and induce local side effects (Brodsky et al., 2012; Majlesi et al., 2007). 
Peripheral spread away from the site of toxin injection is not dependent on auxiliary proteins 
(Brodsky et al., 2012; Carli et al., 2009). BoNT/A traffic from periphery to the CNS via axonal 
route is discussed in Section 6.  
 
3. 1.3 BoNT/A internalization into nerve terminals  
BoNT/A makes the first contact with neuronal terminals by binding to polysialogangliosides in 
the outer side of plasma membrane, which anchor the toxin from extracellular fluid (Simpson 
et al., 2013). Subsequently, the toxin heavy chain binds its high affinity membrane protein 
acceptors, synaptic vesicle protein 2 (SV2) and fibroblast growth factor receptor 3, which 
govern BoNT/A binding and endocytotic entry into neurons (Dong et al., 2006; Jacky et al., 
2013; Mahrhold et al., 2006). BoNT/A internalization into neurons may be mediated by all 
isoforms of SV2 (SV2 A-C), with the strongest affinity for SV2C (Dong et al., 2006). After 
binding to protein acceptors on neuronal membrane, BoNT/A undergoes dynamin-dependent 
endocytosis into the acidic compartment of small synaptic vesicles (Colasante et al., 2013; 
Harper et al., 2011). The process of BoNT/A endocytosis is augmented by neuronal activity, 
which promotes synaptic vesicle recycling (Harper et al., 2011).  
50 kDa BoNT/A light chain (LC) is translocated from small synaptic vesicle into the cytosol by 
a pH-dependent active process mediated by N-terminus translocation domain of heavy chain 
(HN) (Kalandakanond and Coffield, 2001; Fischer and Montal, 2007). HN domain is inserted 
into the vesicle membrane and acts as a chaperone channel, which unfolds the three-
dimensional structure of LC into a polypeptide chain and translocates it from the inside of 
small synaptic vesicle into the cytosol. Under the influence of acidic pH in vesicles, 
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disulphide bridge between the heavy and light chain is reduced during the translocation 
process (Fischer and Montal, 2007). 
 
3. 2. Pharmacodynamics  
3. 2. 1. Proteolytic activity.  
After translocation into the cytosol, LC polypeptide is refolded into a soluble Zn2+-dependent 
metalloprotease (Kalandakanond and Coffield, 2001). At the cytosolic side of presynaptic 
plasma membrane, LC protease hydrolyses a distinct peptide bond on membrane-associated 
protein SNAP-25 (Blasi et al., 1993; Keller et al., 2004; Südhof et al., 2013). SNAP-25 is a 
part of the Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
heterotrimeric complex, which has a pivotal role in fusion of vesicular and plasma membrane 
lipid bilayers during Ca2+ -dependent exocytosis. By cleaving unique peptide bonds on 
SNARE-proteins, different BoNT serotypes and tetanus toxin (TeNT) prevent the fusion of 
neurotransmitter-containing vesicles with presynaptic plasma membrane.  Along with SNAP-
25 (targeted by BoNT serotypes A, E and C1), SNARE complex is comprised of two 
additional proteins: membrane-associated syntaxin (targeted by BoNT/C1) and vesicle-
associated membrane protein(VAMP)/synaptobrevin (targeted by BoNT serotypes B,D,F,G, 
and TeNT) (Binz et al., 1994; Foran et al., 1996; Pelizzari et al., 1999; Schiavo et al., 1992).  
 
3. 2. 2. Duration and extent of BoNT/A–induced synaptic paralysis 
BoNT/A-mediated cleavage of SNAP-25 in cholinergic synapses leads to reversible long-
term prevention of acetylcholine release which, in case of neuromuscular paralysis, can last 
up to 6 months in humans.  
Based on experiments involving introduction of anti BoNT/A LC antibodies into the cytosol 
(Bartels et al., 1993), it was found that, after inhibition of BoNT/A catalytic activity, the 
paralysis may persist for up to 4 days. The delay in recovery was attributed to the time 
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course of synaptic turnover of cleaved SNAP-25 (Keller and Neale, 2001). Thus, this period 
is not sufficient to explain the long lasting effect of BoNT/A (4 days vs several months). The 
dominant mechanism for the long-term duration of BoNT/A activity is the unusual stability of 
its proteolytic light chain in the cytosol. It may persist for at least 180 days in vivo, and 80 
days in vitro in rodents (Antonucci et al., 2008; Keller et al. 1999). Persistence of BoNT/A 
protease in the cytosol is presumably mediated by toxin’s light chain resistance to 
proteasomal degradation (Tsai et al., 2010). BoNT/E LC is more susceptible to proteasomal 
degradation which mediates shorter duration of its effects compared to BoNT/A (Tsai et al., 
2010).  
It is estimated that BoNT/A-mediated cleavage of less than 10% of SNAP-25 is able to cause 
almost complete muscular paralysis (>90%) (Kalandakanond and Coffield, 2001). 
Additionally, in vitro spontaneous cholinergic neurotransmission in cultured autonomic 
neurons is blocked >80% by 1 pM BoNT/A despite cleaving only <20% of the SNAP-25 
(Lawrence et al., 2013). These observations suggest that only a portion of functional SNAP-
25 needs to be cleaved to induce a near-complete synaptic paralysis. Truncated SNAP-25 
lacks only 9 C-terminal amino acids, which does not impair the forming of heterotrimeric 
complex with other two SNAREs (Lawrence et al., 2002; Meunier et al., 2003). Inactive 
SNARE complex by itself may inhibit the neurotransmitter release (Keller and Neale, 2001). 
This is augmented by finding that cell transfection with BoNT/A-truncated SNAP-25 induces 
the inhibition of vesicular release similar to BoNT/A (Huang et al., 1998). It is estimated that 
several SNARE complexes forming a star-shaped oligomer (SNARE supercomplex) are 
necessary for the fusion of single synaptic vesicle with plasma membrane (Meghighian et al., 
2010).  
 
3. 2. 3. Toxicity and clinical potency of BoNT/A 
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BoNT/A dose required to produce clinical symptoms of botulism are minute – required 
quantities are in order of nanograms (LD50 is 70 ng/70 kg person). Effective therapeutic 
doses in different clinical conditions are much lower- in some conditions like spasmodic 
dysphonia in order of picograms (Upile et al., 2009). Main pharmacokinetic and 
pharmacodynamic factors which summate and result in high BoNT/A potency are 
summarized in sections 3. 1. 2- 3. 2. 2. These are:  
- although it is a large protein, fraction of the toxin penetrates into the bloodstream 
through epithelial barriers (Section 3. 1. 2).  
- long elimination half-life of BoNT/A in the systemic circulation allows distribution to 
peripheral tissues and entry into peripheral nerve terminals (Section 3. 1. 2).  
- high affinity of BoNT/A heavy chain to dual ganglioside-protein acceptors at the 
peripheral nerve terminals (Section 3. 1. 3)  
- BoNT/A light chain is an enzyme which may target many SNAP-25 molecules (Section 
3. 2.1).  
- in the cytosol, BoNT/A light chain is very stable and resistant to proteasomal 
degradation, which mediates the long-term effect of BoNTA (Section 3. 2. 2) 
- cleavage of only a small portion of SNAP-25 is required for synaptic paralysis (Section 
3. 2. 2) 
 
3. 3 BoNT/A activity is not restricted to inhibition of SNAP-25-mediated acetylcholine 
release 
3.3.1 Effect on neurotransmitters other than acetylcholine 
Classically, it was assumed that BoNT/A enters cholinergic motor and autonomic neurons 
only. However, it was subsequently discovered that the toxin enters many different neuronal 
types and blocks the neurotransmitter release from non-cholinergic synapses, too. Mostly in 
vitro experiments demonstrated that BoNT/A prevents the release of serotonin, dopamine, 
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noradrenaline, glutamate, gamma-aminobutyric acid (GABA), enkephalin, glycine, Substance 
P and calcitonin gene-related peptide (CGRP) (Nakov et al., 1989, Mc Mahon et al., 1992; 
Welch et al., 2000; Morris et al., 2002; Durham et al., 2004; Verderio et al., 2007).  
 
3.3.2. Preferential effect on excitatory vs. inhibitory neurons.  
BoNT/A is more efficient in impairing the release of excitatory neurotransmitters, such as 
acetylcholine and glutamate, in contrast to GABA (Verderio et al., 2007). This was proposed 
to result from higher transient increase in calcium concentration upon depolarization in 
GABA-ergic neurons, in comparison to excitatory neurons (Grumelli et al., 2010). High 
concentrations of intracellular Ca2+, in turn, have the ability to overcome the cleaved SNAP-
25-mediated paralysis (Gerona et al., 2000; Grumelli et al., 2010; Lawrence et al., 2002). 
Loss of SNAP-25 C-terminus affects the Ca2+-dependent interaction of SNARE complex with 
synaptotagmin I, a protein involved in triggering of Ca2+-mediated neurotransmitter release. 
This interaction can be restored by increasing the Ca2+-concentration (Gerona et al., 2000). 
Since SNAP-25 is also a negative regulator of calcium channels (Pozzi et al., 2007), higher 
level of SNAP-25 in excitatory neurons makes them more BoNT/A-sensitive in comparison to 
inhibitory neurons. Reducing the calcium levels by chelators induces a higher sensitivity of 
GABA-ergic neurons to BoNT/A action (Grumelli et al., 2010; Verderio et al., 2004).  
 
3.3.3. Activity outside of synaptic active zone.  
Thyssen et al. (2010) demonstrated that BoNT/A activity on neurotransmitter release in 
neuronal compartments is not confined only to synapses. Authors showed that BoNT/A 
inhibits the ectopic vesicular release of glutamate and ATP from axons of olfactory receptor 
neurons (Thyssen et al., 2010). BoNT/A effect in axons suggests its activity on 
neurotransmitter release outside of active synaptic zones.  
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3.3.4 Effects on cell types other than neurons.  
BoNT/A blocks the vesicular release from non-neuronal cell types containing SNAP-25-
dependent exocytotic machinery, such as pancreatic beta cell lines (blockage of insulin 
release), chromaffin cells (acetylcholine) and astrocytes (glutamate) (He et al., 2008; 
Lawrence et al., 2002; Kanno and Nishizaki, 2012). BoNT/A effect on acetylcholine release 
from sciatic Schwann cells has also been reported (Marinelli et al., 2012).  
 
3.3.5. Additional actions of BoNT/A mediated by SNAP-25  
Besides its role on neurotransmitter release, SNAP-25 modulates the activity of Ca2+ 
channels and possibly other voltage gated ion channels (He et al., 2008; Ji et al., 2002; Pozzi 
et al., 2007; Zamponi, 2003). By targeting SNAP-25, BoNT/A may prevent the SNARE-
mediated translocation of receptors to plasma membrane, such as N-methy-D-aspartate 
receptor and transient receptor potential vanilloid 1 (TRPV1) (Cheng et al., 2013; Morenilla-
Palao et al., 2004; Shimizu et al., 2012). In addition, it may prevent the G protein interaction 
with SNARE-dependent exocytotic machinery (Gerachshenko et al., 2005).  
Process of neurite extension through the axonal growth cone was shown to be dependent on 
SNAP-25. BoNT/A inhibits axonal cone growth in cultured hippocampal, dorsal root ganglion 
cells, or differentiated pheochromocytoma-12 (PC-12) cells. In addition, BoNT/A prevented 
the dendritic growth in hippocampal neurons. (Grosse et al., 1999; Morihara et al., 1999).The 
fact that SNAP-25 is not localized at presynaptic sites only, but also along axons and 
dendrites (Fig 1) (Galli et al., 1995; Duc and Catsicas, 1995) suggests that SNAP-25 might 
be a multifunctional protein. It was proposed that SNAP-25 (or the whole SNARE complex) 
may mediate various types of membrane fusion events in the entire axonal compartment 
(Duc and Catsicas, 1995). Consequently, BoNT/A-cleaved SNAP-25 presence along 
neuronal processes (Figure 3) suggests that BoNT/A might also have some additional in vivo 
effects which remain to be investigated.  
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3.3.6. Possible additional targets of BoNT/A action other than SNAP-25 
Up to now, SNAP-25 is the only definitively accepted molecular target of BoNT/A action. 
However, according to several in vitro studies there is a defined effect of BoNT-A on cellular 
processes like neuroexocytosis, apoptosis and neurite sprouting which do not necessarily 
depend on enzymatic cleavage of SNAP-25 (Coffield and Yan, 2009; Ishida et al. 2004; 
Proietti et al., 2012; Ray et al., 1993; Ray et al., 1999; Zhang et al., 2013).  
Several studies have shown that the BoNT/A effect on acetylcholine release mediated by 
arachidonic acid pathway may be independent of SNAP-25. In PC12 cell line, arachidonic 
acid or phospholipase A2 activation-induced exocytotic release of acetylcholine was found to 
be prevented by BoNT/A (Ray et al., 1993). Acetylcholine release promoted by arachydonic 
acid or by phospholipase A2 activation was found to be present even when the expression of 
SNAP-25 was prevented by antisense oligonucleotides (Ray et al., 1993; Ray et al., 1999). 
The authors proposed the existence of additional anti-exocytotic mechanisms of BoNT/A 
action not dependent on SNAP-25 (Ray et al., 1999). Recently, it was shown that 
phospholipase A2 activator mastoparan-7 partially reverses the BoNT/A-mediated 
impairment of cholinergic transmission in cultured spinal cord cells (Zhang et al., 2013). The 
effect was suggested to be unrelated to the activity of BoNT/A proteolytic effect on SNAP-25 
(Zhang et al., 2013).  
It was suggested that BoNT/A blocks the lysophosphatidic acid-promoted acetylcholine 
release from differentiated PC12 cells by inhibiting RhoB-dependent signaling pathway 
(Ishida et al., 2004). RhoB protein is a member of Rho kinases/GTP-ases involved in 
intracellular signaling pathways leading to actin reorganization. The authors demonstrated 
that BoNT/A, by an unknown mechanism, promotes the proteasomal degradation of RhoB 
(Ishida et al., 2004).  
BoNT/A induces apoptosis in cell cultures derived from prostate cancer and breast cancer 
(Bandala et al. 2013; Karsenty et al., 2009; Proietti et al., 2012). Lack of neural elements in 
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cell culture suggests that BoNT/A effect are mediated through mechanisms independent 
from neurotransmitter release. In prostate cancer cell lines, BoNT/A increases the 
concentration of phosphorylated phospholipase A2, which is proposed to be associated with 
BoNT/A –mediated apoptosis and inhibition of proliferation (Proietti et al., 2012). 
In another in vitro experiment, neuritogenic sprouting of motor nerve terminals, previously 
believed to be associated with toxin’s paralytic activity on neuromuscular junctions, was 
proposed to be independent of toxin’s light chain (Coffield and Yan, 2009). BoNT/A heavy 
chain subunit was shown to promote the neurite sprouting in cultured motor neurons similarly 
as the native toxin consisting of both light and heavy chain. Authors proposed that the 
binding activity of BoNT/A heavy chain alone is sufficient to promote neuritogenesis (Coffield 
and Yan, 2009).  
Bossowska and Majewski (2012) reported that BoNT/A injection into bladder reduces the 
number of sensory neurons containing substance P, CGRP, calbindin, somatostatin, and 
neuronal nitric oxide synthase in ganglia innervating the bladder. The mechanism of these 
changes might be connected with altered gene expression. Up-regulation of  CGRP and 
enkephalin m-RNA expression in motoneurons after intramuscular BoNT/A has been 
interpreted as indirect consenquence of peripheral chemical denervation (Humm et al., 2000; 
Jung et al., 1997; Palomar 2012; Zhang et al., 1993). 
 
 
4. EVIDENCE OF THE ANTINOCICEPTIVE ACTION OF BONT/A  
 
4. 1. Clinical evidence of BoNT/A’s antinociceptive activity 
 
4. 1. 1. First clinical observations 
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As previously mentioned in Section 2.2, small doses of purified BoNT/A are clinically used for 
treatment of neuromuscular disorders characterized by increased tonicity or overactivity of 
certain muscles (Barnes 2003; Thengannat et al., 2012). Along with the neuroparalytic effect, 
it was observed that BoNT/A reduces the pain associated with the neuromuscular 
hyperactivity disorders, such as dystonic torticollis (Tsui et al., 1986; Brin et al., 1987; Tarsy 
and First, 1999). BoNT/A-mediated pain relief was initially believed to be associated with 
decreased contraction of affected muscles (Arezzo, 2002; Cohen et al., 1989; Mense 2004). 
It was proposed that BoNT/A, by inhibiting the release of acetylcholine in hyperfunctional 
muscular end plates, may indirectly prevent the painful ischemia caused by muscle 
contractures in spasticity and dystonia (Mense, 2004). However, it was reported that the 
observed pain relief in patients treated for spasmodic torticollis was not concurrent with 
neuromuscular effects, since it was present in some patients even when dystonic posture of 
the neck was not improved (Stell et al., 1988). Additionally, BoNT/A-mediated pain relief 
does not always occur simultaneously with the observed paralytic effect in focal dystonias, 
and it sometimes even persists after the neuromuscular benefit is no longer visible (Aoki, 
2003; Freund and Schwartz, 2003; Jankovic et al., 1990; Relja and Klepac, 2002). In a dose 
response double blind study of Relja and Klepac (2002), it was observed that BoNT/A effect 
on pain in spasmodic torticollis occurs after one week, while the beneficial effect on motor 
function started after 2 weeks. Moreover, it was discovered that the dose necessary to 
induce beneficial effect on pain (50 U) was lower than the doses necessary for motor 
improvement (100 and 150 U). In patients treated with BoNT/A for temporomandibular 
disorders it was observed that the beneficial effects on pain persisted longer than the 
decreased voluntary bite force (Freund and Schwarz, 2003). Additionally, based on the 
effectiveness of BoNT/A injections into the myofascial trigger points in treatment of 
myofascial pain, BoNT/A effect was proposed to be linked to either indirect or direct effects 
on pain fibres rather than muscles themselves (Giladi, 1997). Since the onset of BoNT/A 
action on pain did not correspond to the onset of paralytic muscular effects or lasted longer 
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than the paralysis, toxin’s action on sensory or vegetative nerves was suggested (Giladi, 
1997; Mense, 2004).  
Independently from pain which might be related to increased muscle contraction, 
antinociceptive effect of BoNT/A was reported in different types of chronic pain not 
associated primarily with muscular hyperactivity, such as migraine, tension type headache 
and different types of neuropathic pain (Argoff et al., 2002; Relja et al., 1997; Silberstein et 
al., 2000). Along with experimental knowledge obtained from pre-clinical in vitro and in vivo 
studies (Section 5. 2), it is accepted that BoNT/A effects on pain may be mediated by its 
direct effects on sensory system.  
 
3. 1. 2. Current clinical experience 
 
Migraine. Based on the results of large (1384 patients) multicentric Phase III Research 
Evaluating Migraine Prophylaxis Therapy (PREEMPT) studies (Dodick et al., 2010), BoNT/A 
was approved by the FDA for the treatment of chronic migraine (migraine lasting >15 days 
per month) in 2010. Therapeutic outcome was significantly reduced mean number of 
migraine attacks per month, suggesting that BoNT/A may be used as a prophylactic 
treatment of chronic migraine. In mentioned studies BoNT/A was injected into fixed sites over 
several cranial and neck muscles and in fixed doses (total dose of 155-195 onabotulinum 
toxin A preparation units – 1 unit (U) corresponds to intraperitoneal mouse LD50 dose, which 
equals 48 pg of 900 kDa toxin complex). 
The value of PREEMPT study, organized by Allergan (onabotulinum toxin A manufacturer) 
was highly prized (reviewed by Láinez-Andrés, 2012) and questioned at the same time 
because the outcome of some other randomized controlled experiments was mild or not 
found at all (reviewed by Gady and Ferneini, 2013). As pointed out by Frampton (2012) 
“Debate surrounding the PREEMPT studies has centered on the small treatment effect of 
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BoNTA relative to placebo, the possibility that blinding was inadequate and relevance of the 
evaluated population”. It is also possible that some patient subpopulations exhibit a larger 
benefit from BoNT/A use in comparison to others. The directionality of pain may be a marker 
for predictability of BoNT/A responsiveness in the treatment of migraine headache 
(Jakubowski et al., 2005; Silberstein et al., 2009). In the subpopulation of responders, it was 
reported that most of them (84 %) described their headache as a pressure build-up from 
outside (imploding headache), while in the subpopulation of non-responders, 83% of patients 
described their pain as a pressure from inside (exploding headache) (Silberstein et al., 
2009). It was also suggested that pericranial allodynia, unilaterality of migraine pain and 
pericranial muscle tenderness in chronic migraine may be predictive markers for BoNT/A 
responsiveness (Matthew et al., 2008).  
Other types of pain. In the past decade, several hundreds of reports of pain relief due to 
BoNT/A off-label use in various clinical conditions have been published. Beneficial effects in 
pain have been reported in interstitial cystitis (Kuo, 2013, Russell et al., 2013), chronic 
arthritis (Chou et al., 2010), residual limb pain (Wu et al, 2012), different types of neuropathic 
pain (Ranoux et al, 2008; Zuniga et al., 2008) including diabetic neuropathy (Relja and 
Miletić, 2005; Yuan et al., 2009; Chen et al., 2013), masticatory pain etc. Although some 
double-blind, placebo controlled studies have been performed (review by Jabbari and 
Machado, 2011), clinical reports on BoNT/A effectiveness are dominated by studies based 
on a small number of patients or individual case reports. In the literature there is an 
increasing number of rare conditions with reported BoNT/A effectiveness on pain such as 
Parry Romberg syndrome (Borodic et al., 2013), Morton neuroma (Climent et al., 2013), 
painful legs and moving toes syndrome (Rodriguez and Fernandez, 2013), post-thoracotomy 
pain (Fabregat et al., 2013) post-amputation limb pain (Wu et al, 2012), etc.  
Although BoNT/A seems to be a promising candidate for treatment of chronic pain, the 
results of clinical studies are contradictory, such as the effects on myofacial pain (Cheshire et 
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al., 1994; Göbel et al., 2006; Wheeler et al., 1998) and tension type headache (Relja, 1997; 
Relja and Telarović, 2004; Schulte-Mattler et al., 2004).  
Results of systemic reviews and meta-analyses (Cochrane data base systemic reviews and 
other) are also mostly inconclusive: 
- Benign masseter muscle hypertrophy. Fedorowicz et al., (2013) assessed 23 full text 
articles but were unable to identify any randomized clinical trial or controlled clinical trial 
investigating the efficacy and safety of intra-masseteric injections of BoNT/A for people with 
bilateral benign masseter hypertrophy.  
- Winocour et al., (2013) published a systemic review of 7 clinical trials on 427 women with 
subpectoral breast implants. The results suggest that BoNT/A may alleviate postoperative 
pain but this outcome is inconsistent and lacks methodological rigor.  
- Soares et al., (2012) and Gerwin (2012) analyzed the efficacy of BoNT/A in myofascial pain 
syndromes in adults. Based on data from four studies with a total of 233 participants, authors 
concluded that “there is inconclusive evidence to support the use of botulinum toxin in the 
treatment of myofascial pain syndromesZ. Meta-analyses were not possible due to the 
heterogeneity between studies”.  
- Subacute/chronic neck pain. Nine randomized and quasi-randomized controlled trials (503 
participants) were included in the systemic review performed by Langevin et al., (2011). 
However “evidence fails to confirm either a clinically important or a statistically significant 
benefit of BoNT-A injection for chronic neck pain associated with or without associated 
cervicogenic headache. Likewise, there was no benefit seen for disability and quality of life at 
four week and six months”. 
- In systemic review of low-back pain and sciatica Waseem et al. (2011) included three 
randomized trials (N =123 patients). Only one of the three trials had a low risk of bias and 
demonstrated that BoNT injections reduced pain at three and eight weeks and improved 
function at eight weeks compared to saline injections. The second trial showed that BoNT/A 
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injections were better than injections of corticosteroid plus lidocaine or placebo in patients 
with sciatica attributed to piriformis syndrome. The third trial concluded that BoNT/A 
injections were better than traditional acupuncture in patients with third lumbar transverse 
process syndrome. Heterogeneity of studies prevented meta-analysis.  
- Singh and Fitzgerald (2010) analysed BoNT/A efficacy in shoulder pain. They analysed six 
randomized controlled trials with 164 patients receiving either BoNT/A or placebo. BoNT/A 
decreased pain and improved shoulder function in patients with chronic shoulder pain due to 
spastic hemiplegia or arthritis, but the sample size was small, and authors concluded that 
more studies with safety data are needed.  
- Hu et al. (2013) published a systemic review analyzing the outcome of BoNT/A treatment of 
101 patients with trigeminal neuralgia (6 studies: five prospective studies and one double-
blind, randomized, placebo-controlled). Beneficial effect was observed in “approximately 70-
100% of patients”. However, randomized, controlled, double-blinded studies are still lacking.  
- In a large meta-analysis involving 23 studies and more than 5000 patients, Jackson et al. 
(2012) analyzed BoNT/A efficacy in episodic and chronic migraine, chronic daily headache 
and tension type headache. They concluded that BoNT/A may reduce the mean number of 
headache days per month in chronic migraine and chronic daily headache, in comparison to 
placebo. BoNT/A was not beneficial in the treatment of episodic migraine and tension-type 
headache. 
In addition to the small sample size and limited number of randomized controlled clinical 
trials, the reason for contradictory or negative findings can be the lack of standardized 
guidelines for BoNT/A application and dosage, and appropriate definition of study primary 
outcomes (Jabbari and Machado, 2011).  
In spite of controversies, clinical reports on the use of BoNT/A suggest unique long-lasting 
pain reduction after a single local use, lasting 3-6 months. Lasting reduction of pain after 
single BoNT/A application represents the most obvious advantage over classical analgesic 
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drugs, which have a shorter duration of action and need to be taken regularly. Prolonged 
activity in comparison to other analgesics drives the need for further development of the 
BoNT/A use in treatment of chronic pain. Another advantage of BoNT/A use may be the lack 
of serious side effects often associated with certain classic analgesic drugs, such as the 
development of tolerance and medication overuse. Potential important use of BoNT/A is its 
reported efficacy in cases of refractory chronic pain where other treatments have failed.  
 
 
4. 2 Preclinical studies 
 
Up to now, the clinical use of BoNT/A has occurred largely empirically. In PubMed database 
hundreds of clinical reports on the action of BoNT/A on pain (including migraine) can be 
found. In contrast to that, if we subtract review articles and commentaries, there are only few 
dozens of preclinical publications related to BoNT/A and pain in total.  
 
4. 2. 1 Ex vivo and in vitro studies  
 
Ex vivo and in vitro studies showed that BoNT/A inhibits the evoked release of neuropeptides 
which modulate inflammation and pain. In the rabbit iris sphincter muscle, BoNT/A inhibited 
substance P-ergic component of contraction evoked by electric pulse field (Ishikawa et al., 
2000), suggesting that BoNT/A may reduce the peripheral SP release from trigeminal 
afferents. In ex vivo rat bladder preparation, incubation with BoNT/A prevented the release of 
SP and CGRP after acute incubation with HCl or cyclophosphamide-induced chronic cystitis 
(Rapp et al., 2006; Lucioni et al., 2008). BoNT/A inhibited the release of SP evoked by 
capsaicin and K+ in cultured dorsal root ganglion cells (Purkiss et al., 2000; Welch et al., 
2000). BoNT/A effects were dependent on the presence of extracellular Ca2+ (Purkiss et al., 
2000). BoNT/A was similarly effective in reducing K+ or capsaicin-stimulated CGRP release 
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from sensory neurons isolated from trigeminal ganglion, while the basal CGRP release was 
unaffected (Durham et al., 2004). In another study, BoNT/A inhibited the CGRP release from 
trigeminal sensory neurons evoked by K+, bradykinin, and to a lesser degree by capsaicin 
(Meng et al., 2007). In brainstem slices BoNT/A altered the electrophysiologically measured 
basal CGRP drive on secondary trigeminal neurons, but was unable to alter capsaicin-
evoked CGRP drive (Meng et al., 2009). In the same study it was shown that the increase of 
Ca2+ concentration can overcome the BoNT/A-mediated inhibition of K+-stimulated CGRP 
release from trigeminal ganglion neurons (Meng et al., 2009). In cultured sensory ganglia 
BoNT/A prevented the SNARE-mediated TRPV1 translocation to the plasma membrane, 
which is suggested to contribute to its analgesic activity in vivo (Morenilla-Palao et al., 2004; 
Shimizu et al., 2012; Yiangou et al., 2011).  
 
In vitro effect on evoked CGRP release has been screened for different BoNT serotypes: 
BoNT/A, BoNT/B, BoNT/C1, BoNT/D and BoNT/E (Meng et al., 2007; Meng et al., 2009). It 
was shown that BoNT/E cannot inhibit the evoked CGRP release in sensory neurons, since 
SV2A and SV2B protein isoforms, the ectoacceptors for BoNT/E endocytosis, are not 
present in sensory neurons which express SV2C (2009). In contrast to BoNT/E, BoNT/A 
binds all three SV2 isoforms, with highest affinity for SV2C. The effect of BoNT/E protease 
on capsaicin-evoked CGRP release in cultured sensory neurons was established after 
coupling BoNT/E light chain to BoNT/A heavy chain receptor binding domain (HC(A), which 
yielded EA recombinant chimeric protein (Meng et al., 2009).  
 
4. 2. 2. In vivo models 
 
Chemically- induced pain. First preclinical observation of in vivo direct antinociceptive effect 
of BoNT/A was reported in a model of formalin-induced inflammatory pain. Subcutaneous 
BoNT/A was found to reduce the inflammatory hyperalgesia during the second phase of 
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formalin test (Cui et al., 2004; Luvisetto et al., 2006; Vacca et al., 2012; Drinovac et al., 
2013). Intracerebroventricular injection of BoNT/A, in comparison to peripheral injection, had 
similar efficacy in reducing formalin-induced pain (Luvisetto et al., 2006). The effect of 
intrathecal BoNT/A injection has also been reported (Lee et al., 2011). Efficacy of BoNT/A in 
reducing thermal and mechanical hyperalgesia was reported in other models of acute 
inflammatory somatic pain evoked by carrageenan and capsaicin (Bach-Rojecky and 
Lacković, 2005; Favre-Guilmard et al., 2009; Shin et al., 2013). A recent study reported that 
BoNT/A is equally effective after single and repeated injections in a model of formalin-
induced orofacial pain (Matak et al., 2013).  
Neuropathic pain. BoNT/A effectiveness in nerve injury-evoked neuropathic pain was found 
in partial sciatic nerve transection model (Bach-Rojecky et al., 2005), wherein it reduced the 
thermal and mechanical hyperalgesia. In the same model BoNT/A was also shown to reduce 
the mechanical and cold allodynia (Drinovac et al., 2013). Further studies of neuropathic pain 
reported that BoNT/A reduced the mechanical and cold allodynia in spinal nerve ligation 
model (Park et al., 2006). Later, its efficacy in reducing mechanical allodynia was reported in 
sciatic nerve constriction-injury-evoked neuropathy (Luvisetto et al., 2007; Marinelli et al, 
2010; Mika et al., 2011). It was observed that BoNT/A accelerates the functional recovery of 
the injured sciatic nerve in a model of sciatic constriction injury-induced peripheral 
neuropathy, measured using sciatic static index and regeneration-associated markers 
(Marinelli et al., 2010; Mika et al., 2011; Pavone and Luvisetto 2010). In addition, BoNT/A 
prevented the sciatic nerve injury-induced upregulation of pronociceptive opioid 
neuropeptides and SNAP-25 in the sensory ganglia, and markers of glial activation in the 
spinal cord (Mika et al., 2011; Vacca et al., 2013). These effects were proposed to contribute 
to analgesic activity of BoNT/A in neuropathic pain. In a model of chronic constriction injury 
of the infraorbital nerve, BoNT/A reduced the mechanical allodynia and thermal hyperalgesia 
(Kitamura et al., 2009; Filipović et al., 2012; Kumada et al., 2012). Along with its analgesic 
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activity, it also reduced the accompanying neurogenic inflammation of cranial dura mater 
(Filipović et al., 2012).  
Bilateral pain. BoNT/A efficacy in bilateral pain induced by repeated intramuscular acidic 
saline injection and diabetic pain evoked by streptozootocin was reported after both 
peripheral and intrathecal injections (Bach-Rojecky and Lacković, 2009; Bach-Rojecky et al., 
2010). BoNT/A was effective in reducing polyneuropathic pain evoked by chemotherapeutic 
drug paclitaxel (Favre-Guilmard et al., 2009). BoNT/A reduced the bilateral pain evoked by 
ventral root transection (Xiao et al., 2011; Xiao et al., 2013). In these models, unilateral 
peripheral BoNT/A injection exerted a bilateral antinociceptive effect. (For details on these 
studies see section 5. 3.)  
Other types of pain. Apart from somatic pain, its efficacy was reported in animal models of 
acute and chronic visceral pain. BoNT/A prevented the acetic acid-induced bladder pain and 
capsaicin-evoked prostatic pain, as well as chronic cystitis evoked by cyclophosphamide 
(Chuang et al., 2004; Chuang et al., 2008; Chuang et al., 2009). Additionally, BoNT/A 
efficacy was reported in postsurgical pain (Filipović et al., 2009) and CFA-induced chronic 
knee arthritis (Krug et al., 2009).  
In vivo efficacy of other BoNT serotypes and their recombinantly-engineered combinations. 
BoNT/B efficacy was investigated for the first time in a model of formalin-induced pain in 
mice (Luvisetto et al., 2006). Peripherally administered BoNT/B, in contrast to BoNT/A, 
reduced the phase I of formalin-induced pain, while it had no effect on phase II hyperalgesia. 
Intracerebroventricularly administered BoNT/B had a pro-hyperalgesic activity on the 
interphase between phase I and phase II of formalin-induced pain (Luvisetto et al., 2006). In 
a mouse model of chronic knee arthritis induced by collagenase IV intraarticular injection, 
BoNT/B reduced the joint tenderness and significantly improved the gait score (Anderson et 
al., 2010). In mice, intrathecally applied BoNT/B reduced the phase II of formalin induced 
pain and neurokinin-1 receptor internalization in the dorsal horn evoked by central substance 
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P release (Huang et al., 2011). In the in vivo model of capsaicin-evoked pain it was shown 
that a recombinant protein chimera consisting of BoNT/E LC coupled to proteolytically 
inactive full length BoNT/A may induce a prolonged analgesic activity (Dolly et al., 2011). It 
seems that proteolytically inactive BoNT/A facilitated the BoNT/E LC entrance into sensory 
neurons. Additionally, BoNT/A part of the molecule protected the BoNT/E LC from 
proteasomal degradation, enabling its prolonged activity (Dolly et al., 2011). Recently, 
analgesic efficacy of chimeric BoNT/A LC coupled to TeNT Hc was demonstrated in 
complete Freund’s adjuvant-induced inflammatory pain (Ferrari et al., 2013).  
 
4. 3 Peculiar properties of BoNT/A antinociceptive activity 
  
Unlike most analgesics which affect acute nociceptive pain thresholds, BoNT/A shows a 
considerable selectivity only in lasting types of pain associated with central sensitization. 
BoNT/A primarily seems to lower hyperalgesic or allodynic responses in acute inflammatory 
or chronic pain. BoNT/A does not alter normal nociceptive thresholds or acute nociceptive 
pain in both humans and animals, as well as phase I of formalin-induced experimental pain 
(Blersch et al., 2002; Cui et al., 2004; Bach-Rojecky et al., 2005).  
Together with the observed lack of effect on acute nociceptive pain, another important 
difference between the classical analgesics and BoNT/A is the lack of defined dose-response 
effects on pain, i.e. the correlation between the dose of peripherally delivered toxin and 
observed antinociceptive effect (Bach-Rojecky et al., 2005; Bach-Rojecky and Lacković, 
2005; Bach-Rojecky et al., 2010). At lower toxin doses which do not impair the motor 
performance, it seems that the full analgesic effect is exerted already at the lowest effective 
dose (Bach-Rojecky and Lacković, 2005; Bach-Rojecky et al., 2010). For example, at 3 U/kg 
BoNT/A seems not to affect the carrageenan and capsaicin-evoked pain, but at slightly 
higher dose (3. 5 U/kg), and further increased doses (5 and 7 U/kg) BoNT/A exerts similar 
and maximal analgesic activity (Bach-Rojecky and Lacković, 2005). In formalin test similar 
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antinociceptive effect of 3.5, 7 and 15 U/kg BoNT/A doses was reported (Cui et al., 2004). In 
few studies the authors described the increased analgesic effects occurring at high doses of 
toxin applied (20-40 U/kg) (Cui et al., 2004; Park et al., 2006).  However, systemic spread of 
BoNT/A impaired the animal motor performance, which most likely interfered with the ability 
to produce a nocifensive reaction (Cui et al., 2004). Up to now, clinical trials also did not 
address the dose response of BoNT/A, and the doses employed were defined only 
empirically.  
 
 
5. PERIPHERAL OR CENTRAL MECHANISM OF BONT/A’S ANTINOCICEPTIVE 
ACTIVITY 
 
5. 1 Peripheral theory of BoNT/A’s antinociceptive effects 
 
As an explanation of its antinociceptive effect it was suggested that BoNT/A, similarly to well-
known prevention of acetylcholine release from neuromuscular junction, inhibits the local 
neurotransmitter release from sensory nerve endings by peripheral SNAP-25 cleavage (Cui 
et al., 2004; Aoki, 2005; Aoki and Francis 2011; Wheeler and Smith, 2013). This suggestion 
was based primarily on the observation of Cui et al. (2004), who found that subcutaneous 
injection of BoNT/A reduces the licking activity during the second (inflammatory) phase of 
pain induced by subcutaneous injection of formalin. BoNT/A did not reduce the initial phase 
of licking behavior caused by direct chemical stimulation of peripheral nerve endings with 
formalin. Selective reduction of inflammatory pain was accompanied by inhibition of formalin-
induced increase of peak glutamate concentration in the rat hind-paw, and reduction of paw 
edema, assumed to be a consequence of neurogenic inflammation. Antinociceptive activity 
of BoNT/A was therefore suggested to be linked with its peripheral anti-inflammatory effects 
(Aoki, 2005; Cui et al., 2004). It was proposed that cleavage of SNAP-25 at peripheral 
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endings of sensory nerves results in consecutive prevention of release of neurotransmitters 
which mediate pain and inflammation (Aoki 2005; Aoki and Francis, 2011; Wheeler and 
Smith, 2013). The authors hypothesized that BoNT/A may reduce the peripheral release of 
not only glutamate, but also of neuropeptides involved in neurogenic inflammation such as 
substance P (SP) and calcitonin gene-related peptide (CGRP) (in the report of Cui et al. 
(2004), peptides were not directly measured) (Aoki, 2005; Cui et al, . 2004). The effect of 
BoNT/A on the release of proinflammatory mediators was demonstrated mostly in in vitro and 
ex vivo experiments (Section 4.2.1). In addition, the suppressive effect of BoNT/A on 
neuronal activation, measured as formalin-induced c-Fos expression or electrophysiologically 
measured activation of wide dynamic range neurons in lumbar dorsal horn was reported 
(Aoki, 2005). The authors proposed that BoNT/A, by preventing the peripheral release of 
neurotransmitters, indirectly reduces the central sensitization (Aoki, 2005; Aoki and Francis 
2011).  
Antinociceptive and anti-inflammatory effects of BoNT/A was reported in a human model of 
capsaicin-induced pain (Gazerani et al., 2006; Gazerani et al., 2009; Tugnoli et al., 2007). 
Gazerani et al. (2006, 2009) reported a reduction of pain and capsaicin-induced vasomotor 
reactions in the human skin within the trigeminal area. Similar anti-inflammatory effects were 
observed by Tugnoli et al. (2007), who reported that BoNT/A reduced pain and capsaicin-
induced neurogenic effects in human skin in the area pre-treated by BoNT/A. Contrary to 
these reports, studies of Schulte-Mattler et al. (2003) and Voller et al. (2007) did not report 
significant anti-inflammatory or antinociceptive effects of BoNT/A on capsaicin-evoked pain in 
humans. The differences between the described studies might be related to the experimental 
setup regarding the mode of toxin injection (subcutaneous, intramuscular or intradermal) or 
different BoNT/A doses (Gazerani et al., 2006; Gazerani et al., 2009; Schulte-Mattler et al., 
2003; Tugnoli et al., 2007; Voller et al., 2007). Additionally, BoNT/A does not reduce the 
experimental inflammatory pain evoked by UV light in humans (Sycha et al., 2006).  
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5. 2 Dissociation of BoNT/A antinociceptive activity and peripheral anti-inflammatory 
effects 
 
As mentioned in the previous section, BoNT/A was found to reduce the formalin-induced 
inflammation, increased glutamate content in hind paw tissue, and inflammatory phase 
hyperalgesia (Aoki, 2005; Cui et al., 2004). At the time, it was logical to assume that the 
relation between BoNT/A effect on inflammation and pain is causal – BoNT/A indirectly 
reduces the pain and central sensitization by reducing peripheral 
neurotransmitter/inflammatory mediator release. However, the relation between the effects of 
BoNT/A on peripheral inflammation and pain could not be confirmed in subsequent reports 
(Bach-Rojecky et al., 2005; Bach-Rojecky et al., 2008; Favre-Guilmard et al., 2009; Shin et 
al., 2013).  
In experimental carrageenan or capsaicin-induced inflammatory pain, BoNT/A normalized 
the mechanical and thermal hyperalgesia, but neither local tissue inflammatory edema and 
proinflamatory cell infiltration evoked by carrageenan, nor plasma protein extravasation 
induced by capsaicin were reduced by BoNT/A (Bach-Rojecky et al., 2005; Bach-Rojecky et 
al.,  2008; Favre Guilmard et al., 2009; Shin et al., 2013). These experiments demonstrated 
that the antinociceptive and anti-inflammatory effects of BoNT/A are not necessarily 
connected as it should be expected if both were mediated by reduced peripheral release of 
proinflammatory neuropeptides (Bach-Rojecky et al., 2008). In the study of Cui et al., (2004), 
reduction of formalin-evoked paw edema was significant at a 7 U/kg dose, and was not 
different from control at 3.5 U/kg. Both doses produced similar antinociceptive effect without 
significant difference (Cui et al., 2004). Although the authors suggested that BoNT/A-
mediated pain reduction is associated with decrease of peripheral inflammatory mediator 
release (Cui et al., 2004), there is a difference between the minimal BoNT/A doses needed to 
produce the anti-inflammatory and antinociceptive effects.  
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Dissociation between anti-inflammatory and antinociceptive effects of BoNT/A was also 
reported by a human experimental studies. Tugnoli et al. (2007) observed pain reduction only 
when capsaicin was administered to toxin-pretreated area, but not when injected in the area 
adjacent to toxin treatment. On the contrary, neurogenic flare and vasodilatation was 
reduced even if capsaicin was administered adjacently to the toxin-pretreated area, but the 
pain was not affected. Based on this observation the authors proposed that the toxin’s anti-
inflammatory effect on neurogenic flare and vasodilatation do not significantly contribute to 
BoNT/A-mediated pain reduction (Tugnoli et al., 2007). Similar conclusion was proposed in 
the human study of Krämer et al. (2003) which reported that BoNT/A reduced neurogenic 
flare evoked by cutaneous electrical stimulation, however, with very limited analgesic effect. 
The authors suggested that the neuropeptide-mediated reduction of peripheral neurogenic 
inflammation does not contribute significantly to BoNT/A analgesic effects observed in 
clinical pain syndromes (Krämer et al., 2003).  
Independently of potential connection between its anti-inflammatory and antinociceptive 
effects, it was observed that peripherally delivered BoNT/A has significant antinociceptive 
effect in types of pain where neither peripheral neurotransmitter release nor peripheral 
inflammation have important role, such as bilateral hyperalgesia induced by intramuscular 
acidic saline (described in Section 3. 4) (Sluka et al., 2001; Bach-Rojecky et al., 2009).  
 
 
5. 3 Effects on bilateral pain: indication of central action of BoNT/A 
 
Bilateral pain model studies reported bilateral effects of unilaterally administered BoNT/A 
(Bach Rojecky et al., 2005; Lacković et al., 2006; Bach-Rojecky and Lacković, 2009; Favre 
Guilmard et al., 2009; Bach Rojecky et al. 2010; Xiao et al., 2011; Filipović et al., 2012; Xiao 
et al., 2013). BoNT/A’s distant contralateral effects, obviously, cannot be explained only by 
BoNT/A action on peripheral nerve endings of injected side.  
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Bilateral hyperalgesia induced by intramuscular acidic saline.  
Mirror pain is defined as the occurrence of mechanical sensitivity in the uninjured 
contralateral “mirror image” body structures after unilateral injury, possibly mediated by 
diffusible signaling molecules or bilateral neural pathways at the spinal cord level 
(Koltzenburg et al., 1999). Mirror pain might also involve bilateral supraspinal structures and 
descendent facilitatory pathways (Da Silva et al., 2010). 
In our laboratory, the effect of BoNT/A on centrally mediated mirror pain was examined in a 
model of bilateral muscular hyperalgesia (Bach-Rojecky et al. 2005; Bach-Rojecky and 
Lacković 2009). In this model, two injections of acidic saline (pH=4) into the gastrocnemius 
lead to development of bilateral mechanical hyperalgesia on both hind-limbs (Sluka et al., 
2001). Bilateral hyperalgesia induced by intramuscular acidic saline injections was proposed 
to be mediated by central sensitization and supraspinal bilateral pathways (Sluka et al., 
2001; Da Silva et al., 2010). Hypothetically, if the BoNT/A antinociceptive action is mediated 
by the prevention of peripheral neurotransmitter release, then it shouldn’t reduce the 
contralateral acidic saline-induced bilateral hyperalgesia. Toxin’s effect on the level of CNS 
seems the only convincing explanation. The puzzling fact is that the toxin injected into the 
contralateral limb reduced the pain on that side only, ruling out a possible systemic diffusion 
of BoNT/A.  
Paclitaxel-induced polyneuropathy. Bilateral effects of unilateral toxin injection were also 
observed in models of peripheral polyneuropathies induced by chemotherapeutic drug 
paclitaxel (Favre-Guilmard et al., 2009), and beta-cytotoxic drug streptozotocin which 
induces type I diabetes (Bach-Rojecky et al., 2010). Paclitaxel-induced polyneuropathy in 
rats develops after intraperitoneal high-dose injection of chemotherapeutic, resulting in 
bilateral decrease of hind-paw mechanical withdrawal thresholds. After BoNT/A injection into 
one hind-paw, decrease in mechanical withdrawal thresholds was reversed on both hind-
paws. Since BoNT/A injected contralaterally failed to reduce pain evoked by unilateral 
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carrageenan, the authors ruled out possible systemic spread of BoNT/A as the mechanism of 
bilateral effect (Favre-Guilmard et al., 2009).  
Experimental diabetic pain. In a model of streptozootocin-induced diabetes accompanied by 
increased sensitivity to pain (neuropathy), BoNT/A injected unilaterally induced the bilateral 
effect on mechanical pain. The effect of BoNT/A was delayed: it was evident on 5th day after 
BoNT/A injection, but not after 24 h. However, after intrathecal injection of peripherally 
ineffective low dose (1 U/kg), BoNT/A effect occurred within 24 h (Bach-Rojecky et al., 2010).  
Due to systemic polyneuropathic effect of paclitaxel, and widespread neuropathy occurring in 
experimental diabetes type I, pathological neuronal changes are bilaterally symmetric 
regarding the side of BoNT/A injection. Bilateral effect of unilaterally delivered BoNT/A is 
therefore difficult to explain without considering a central site of action. Bilateral effects after 
unilateral toxin injections were also reported in models of neuropathic pain induced by ventral 
root transection (Xiao et al., 2011; Xiao et al., 2013), and infraorbital nerve constriction 
(Filipović et al., 2012). It seems that BoNT/A bilateral effect on bilateral and mirror pain 
models is a general rule, i.e. not dependent on the type of experimental pain.  
In some studies, the onset of the antinociceptive effect in formalin-induced pain and 
experimental model of inflammatory pain (Cui et al., 2004; Mika et al., 2011) started within 24 
h. However, most of other studies reported the delay of antinociceptive activity of up to 5-7 
days, while peripheral neuromuscular paralysis in animals usually occurs within 24 h (Bach 
Rojecky et al. 2005, Bach-Rojecky and Lacković, 2009; Bach-Rojecky et al., 2010; Chuang 
et al., 2004; Filipović et al., 2012). In addition, BoNT/A’s antinociceptive activity occurred 
within 24 h when applied intrathecally at peripherally ineffective doses (Bach-Rojecky et al., 
2010). The observed faster onset of antinociceptive activity of BoNT/A after central 
application is difficult to explain by presumed peripheral site of BoNT/A action (Bach-Rojecky 
et al., 2010). Based on the bilateral effect and faster onset of action of intrathecally applied 
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small BoNT/A dose, the authors proposed that BoNT/A effect was centrally mediated (Bach-
Rojecky et al., 2010).  
 
 
6. AXONAL TRANSPORT OF BONT/A 
 
Behavioral data obtained from bilateral pain models suggested that BoNT/A effect on pain 
might involve toxin movement and direct activity in the CNS. Hematogenous route as the 
underlying pathway for penetration into the CNS is unlikely since low doses of BoNT/A used 
did not induce systemic poisoning. In addition, BoNT/A is a large protein (150 kDa) which 
cannot cross the blood-brain barrier. The other possible explanation is the axonal transport of 
BoNT/A from periphery to CNS. However, the axonal transport of BoNT/A, up to recently, 
was classically believed to be limited, and toxin activity in the brain following peripheral 
delivery was questionable (Section 6.1) 
 
 
6. 1. Early studies of BoNT/A axonal transport to CNS 
 
It is widely known that BoNT/A induces local paralysis when injected into the muscles treated 
for neuromuscular disorders or cosmetic use. In the literature, due to the prevailing opinion 
that BoNT/A axonal transport is either too slow or non-existent, and the lack of clinically 
observable central side-effects, the possibility of direct central action of BoNT/A has largely 
been neglected. Although the possibility of retrograde axonal traffic to the spinal cord was 
hypothesized during the early preclinical research of BoNT/A, prevailing opinion remained 
that BoNT/A effects are exclusively locally mediated (Aoki and Francis, 2011; Tang-Liu et al., 
2003). 
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As suggested by some earlier studies, the toxin might penetrate into the central nervous 
system by axonal transport (Habermann et al., 1974; Wiegand et al., 1976; Wiegand and 
Wellhöner 1977). To trace the possible spread of BoNT/A into the CNS, the authors 
employed 125I-radiolabelled BoNT/A injections into the cat gastrocnemius muscles. Following 
injection of 125I-labeled BoNT/A, progressive movement of radioactivity was detected along 
the neuronal pathway directed to CNS: firstly in the sciatic nerve, followed by ipsilateral 
spinal ventral roots. In the end, radioactivity was detected in the corresponding ipsilateral 
spinal cord segments 48 h following the toxin’s injection. However, these studies could not 
demonstrate that enzymatically active BoNT/A reached the CNS. Other studies also reported 
that the peripherally injected BoNT/A is transported retrogradely within the axonal 
compartment (Black and Dolly, 1986). Nevertheless, due to the slow axonal traffic it was 
argued that the toxin is likely to be inactivated before it reaches the CNS (Black and Dolly, 
1986). More recently, Tang-Liu et al. (2003) injected radioiodinated neurotoxin complex into 
the gastrocnemius muscle of rats (70 U) and eyelids of rabbits (24 U). The diffusion of 
radioactivity from the site of injection was measured at different time-points (0. 5, 2, 6, 24 and 
48 h post-injection). The authors reported that the majority of neurotoxin remained localized 
at the site of injection. Following the intramuscular injection, radioactivity was detected in 
sites distal to the injection site. In particular, significant amounts were recovered from thyroid 
gland and contralateral muscles. However, the authors suggested that this radioactivity did 
not appear to represent an intact neurotoxin and it was assumed that the signal may be 
associated with non-toxic proteins of the complex, or 125I which dissociated from the complex 
(Tang-Liu et al., 2003).  
 
 
6. 2. Behavioral and pharmacological evidence for the necessity of BoNT/A axonal 
transport for its antinociceptive activity 
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6. 2. 1 Axonal transport necessary for BoNT/A antinociceptive activity occurs in sensory 
neurons 
The importance of axonal transport of BoNT/A for its antinociceptive activity was 
demonstrated behaviorally for the first time in a model of acidic saline-induced bilateral 
mechanical hyperalgesia (Bach Rojecky and Lacković, 2009). In line with the proposed 
central site of action, an injection of small dose BoNT/A (0.5 U/kg) into the stump of a distally 
transected sciatic nerve was still able to reduce the acidic saline-induced hyperalgesia on the 
contralateral side. This experiment excluded the involvement of peripheral nerve endings as 
the indirect site of BoNT/A action on the contralateral side. In addition, it suggested BoNT/A 
retrograde axonal movement within peripheral nerve. Indeed, the axonal transport blocker 
colchicine injected into the sciatic nerve ipsilaterally to BoNT/A peripheral treatment 
eliminated the antinociceptive effect on both sides. This observation suggested that BoNT/A 
requires axonal transport along the sciatic nerve in order to exhibit its antinociceptive effect. 
Colchicine injected into the contralateral sciatic nerve did not affect BoNT/A action on either 
side, ruling out the possibility of toxin spread to nerve endings of contralateral hind-limb. This 
set of observations indicated that BoNT/A axonal transport occurs through peripheral nerves 
and is directed to CNS, but it has remained unknown whether the transport occurs in motor 
neurons or sensory neurons (Bach Rojecky and Lacković, 2009).  
To investigate whether the BoNT/A traffic occurs through sensory neurons, its axonal 
transport was further studied in trigeminal system. Injections of low doses of BoNT/A into the 
whisker pad (3. 5 U/kg) reduced formalin-induced orofacial pain and allodynia induced by 
experimental trigeminal neuropathy (Filipović et al., 2012; Matak et al., 2011). Effect on pain 
was prevented by axonal transport blocker colchicine injected into the trigeminal ganglion 
(Filipović et al., 2012; Matak et al., 2011) Sensory character of trigeminal ganglia suggests 
that axonal transport occurs indeed in sensory axons. In line with that suggestion, 
antinociceptive effect in orofacial formalin test occurred also after direct BoNT/A injection (1 
U/kg) into the trigeminal sensory ganglion (Matak et al., 2011). The onset of antinociceptive 
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action of intraganglionic BoNT/A was, however, delayed. It occurred 2 d after toxin delivery 
into the ganglion. Intraganglionic colchicine also prevented the BoNT/A antinociceptive effect 
when toxin was delivered directly into the ganglion. Delayed action upon ganglionic delivery 
and necessity of axonal transport suggested that BoNT/A, in order to reduce pain, must be 
anterogradely transported further from ganglion into the CNS.  
Interestingly, peripherally induced pain in trigeminal area was accompanied by neurogenic 
extravasation of plasma proteins (measured spectrophotometrically with Evans blue dye) in 
the cranial dura mater. Peripherally delivered BoNT/A prevented this phenomenon and the 
action was, again, colchicine sensitive i. e. axonal transport dependent (Filipović et al., 
2012).  
 
6. 2. 2 Effects of BoNT/A in sensory ganglia  
 
Kitamura et al. (2009) showed that BoNT/A inhibits the vesicular release from trigeminal 
ganglion neurons acutely isolated from animals with experimental trigeminal neuropathy and 
treated with BoNT/A peripherally. As the explanation for the effect on vesicular release 
(measured by FM4-64 dye), the authors proposed BoNT/A axonal transport from periphery 
and transcytosis within the trigeminal ganglion. Novel study reported reduction of TRPV1 
expression within the trigeminal ganglion neurons projecting to cerebral dura mater after 
BoNT/A facial injection (Shimizu et al., 2012). Since neurons innervating dura and periphery 
are different, the authors suggested axonal transport of BoNT/A in primary sensory neurons 
but, also, a possible transcytosis of BoNT/A between different sensory neurons in the 
ganglion. It was proposed that BoNT/A may modulate SNARE-mediated TRPV1 
translocation to the plasma membrane of sensory neurons (Shimizu et al., 2012).  
BoNT/A effects at the level of sensory ganglion were also reported in a model of ventral root 
transection-induced neuropathy. It was found that BoNT/A prevented the up-regulation of 
pain receptors purinergic receptor P2X3 and transient receptor TRPV1. The authors 
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proposed that BoNT/A-mediated pain reduction may be linked to reduced expression of 
receptors and ion channels involved in pain pathophysiology (Xiao et al., 2011; Xiao et al., 
2013).  
 
 
 6. 3. Neurophysiological evidence for axonal transport of BoNT/A 
 
6. 3. 1 Studies in humans 
Studies performed in animals suggest that retrograde axonal transport of BoNT/A occurs 
regularly after low-dose peripheral injections and via different routes of administration (Bach-
Rojecky et al., 2009, Filipović et al., 2012; Matak et al., 2011). Although the BoNT/A axonal 
transport in humans has never been assessed directly, several neurophysiological studies 
reported central effects after peripheral BoNT/A application. Already in 1963 Tyler reported 
alterations of the H reflex in a man with botulism, indicative of alterations at the spinal level 
(Tyler, 1963). Similar observations suggested that the axonal transport of BoNT/A to CNS 
might also exist in humans treated clinically for neuromuscular disorders or intoxicated with 
BoNT/A (Garner et al., 1993; Marchand-Pauvert et al., 2012; Santini et al., 1999; Wohlfart et 
al., 2001; reviewed recently by Caleo and Schiavo, 2009; Palomar, 2012). By employing 
single fiber electromyography, Garner et al. (1993) reported reduced activity of the distant, 
non-injected muscle (extensor digitorum brevis) in patients treated with BoNT/A for focal 
dystonia in the head and neck region. Authors discussed the possibility of a very efficient 
local uptake of BoNT/A and retrograde axonal transport to the CNS (Garner et al., 1993). In 
another study performed in patients treated with BoNT/A for spasmodic torticollis and writer’s 
cramps, the remote changes in motoneuronal excitability (F-wave changes) were observed 
(Wohlfart et al., 2001). Authors ruled out possible BoNTA diffusion to remote muscles or 
distant muscle spindle afferents. As a possible explanation, BoNT/A action on the level of 
motoneuronal bodies in CNS was proposed (Wohlfart et al., 2001).  
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Recently, possible existence of BoNT/A axonal transport via motoneuronal axons and 
recurrent axonal collaterals to CNS in humans was reported by Marchand-Pauvert et al. 
(2013). They measured recurrent inhibition in the injected and non-injected leg muscles in 
patients treated for spasticity. The authors observed depressed recurrent inhibition of distant, 
non-injected muscles. Although it cannot be completely ruled out, they argued against 
indirect or systemic BoNT/A effect. Distant changes of recurrent inhibition suggest a direct 
BoNT/A effect at the cholinergic synapse between recurrent collaterals of primary 
motoneurons and Renshaw interneurons in the ventral horn (Marchand-Pauvert et al., 2013). 
Possibility that peripherally delivered BoNT/A may target SNAP-25 in ventral horn cholinergic 
synapses was experimentally confirmed by immunohistochemistry in rats (Matak et al., 
2012).  
 
6. 3. 2. Neurophysiological evidence for BoNT/A axonal transport in animals 
Few neurophysiological studies in experimental animals employing high doses of BoNT/A 
reported indicated a possibility of BoNT/A retrograde spread into the CNS. BoNT/A 3 ng 
injection into the cat abducens muscle produced alterations in the discharge pattern of 
abducens motoneurons. This was accompanied by ultrastructural synaptic alterations at the 
level of motoneuronal cell bodies (Moreno-Lopez et al., 1997; Pastor et al., 1997). The 
authors suggested retrograde and possible transsynaptic spread of high-dose BoNT/A.  
Recently, possible retrograde and transsynaptic traffic of BoNT/A was reported (Torii et al., 
2011; Akaike et al., 2013). Injection of BoNT/A subtypes A1 and A2 at high doses into rat 
forelimb or hindlimb exhibited a dose-dependent bilateral muscle relaxation. Interestingly, 
contralateral effects of BoNT/A1 (commercially available onabotulinumtoxin A) were partially 
mediated by axonal transport. Contralateral effects of BoNT/A2 serotype, occurring only at 
very high doses, were mediated by systemic diffusion. The authors suggested that BoNT/A1 
is retrogradely transported to the CNS, and then anterogradely into the contralateral muscle 
(Akaike et al., 2013; Torii et al., 2011). The authors also reported BoNT/A distant effect on 
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glycinergic transmission in the dorsal horn, and suggested toxin’s transcytosis to glycinergic 
synapses (Akaike et al., 2013).  
 
 
6. 4. Axonal transport of enzymatically active BoNT/A in the CNS and motoneurons  
 
By employing BoNT/A enzymatic activity detection, axonal transport of active BoNT/A 
molecules was found in the rodent visual system and facial nerve using an antibody specific 
to the product of BoNT/A proteolytic activity (Antonucci et al., 2008). Unlike radioactively-
labeled toxin, cleaved SNAP-25 detection suggests presence of enzymatically active BoNT/A 
protease. Single BoNT/A molecule may enzymatically cleave many SNAP-25 molecules, 
leading to higher sensitivity of detection. Cleaved SNAP-25 can then be detected by 
immunohistochemistry and Western blot.  
Antonucci et al. (2008) demonstrated that the unilateral hippocampal injection of BoNT/A 
resulted in toxin traffic from injection site via direct axonal projections: namely, to 
contralateral hippocampus and ipsilateral entorhinal cortex. Moreover, BoNT/A applied into 
the unilateral hippocampus reduced the neuronal hippocampal activity in contralateral 
hemisphere. Additionally, BoNT/A injected into the superior colliculus was axonally 
transported to the contralateral retina and ipsilateral visual cortex (Antonucci et al., 2008). 
BoNT/A injected into the facial whisker muscles resulted in occurrence of cleaved SNAP-25 
in facial motor nucleus 3 days after the peripheral injection. This observation suggested that 
peripherally administered BoNT/A may be retrogradely transported to the brainstem via facial 
motor neurons (Antonucci et al., 2008).  
Study of Antonucci et al. (2008) was, however, criticized due to the use of high doses of non-
commercial preparation of BoNT/A (Alexiades-Armenakas, 2008). Additional questions were 
raised regarding the ability of antibody-based detection method to discriminate between 
cleaved and non-cleaved SNAP-25 protein (Aoki and Francis, 2011). In later studies which 
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employed the same antibody to cleaved SNAP-25 as in study from Antonucci et al. (2008), 
these questions were answered (Matak et al., 2011; Matak et al., 2012). Central SNAP-25 
cleavage was detected in CNS even at low doses of peripherally injected commercially 
available onabotulinum toxin A (Matak et al., 2011; Matak et al., 2012). When BoNT/A was 
injected into the gastrocnemius muscle (5 U/kg), cleaved SNAP-25 was detected in 
corresponding ipsilateral segments of lumbar spinal cord. These studies indicated that 
BoNT/A axonal transport to CNS occurs regularly at low peripheral doses of commercially 
available BoNT/A, comparable to doses used clinically (Matak et al., 2011; Matak et al., 
2012).  
Antibody specificity for BoNT/A-cleaved form of SNAP-25 was verified by comparing Western 
blot signals of control and BoNT/A-injected rat hippocampus (Matak et al., 2011). 24 kDa 
signal belonging to cleaved SNAP-25 appeared only in toxin-injected brain tissue. Position of 
the 24 kDa signal, detected first by the antibody to cleaved SNAP-25, was subsequently 
confirmed by a well-characterized antibody binding both intact and cleaved SNAP-25. This 
experiment demonstrated that the antibody specifically targets the BoNT/A-cleaved 
sequence of C-terminal SNAP-25 and not the whole SNAP-25 protein (Matak et al., 2011).  
Based on an in vitro study of BoNT/A movement in sympathetic neurons, Lawrence et al. 
(2011) argued that BoNT/A and BoNT/E spread within cell bodies and distal neuronal 
processes may occur due to passive diffusion. However, it was demonstrated in vivo that 
BoNT/A enzymatic activity in ipsilateral lumbar spinal cord, occurring after its injection into 
the sciatic nerve, can be prevented by intrasciatic colchicine. Prevention of occurrence of 
central cleaved SNAP-25 by colchicine demonstrated that the traffic of BoNT/A within 
peripheral nerves to CNS involves a colchicine-sensitive, microtubule-dependent axonal 
transport (Matak et al., 2012). Time required for occurrence of truncated SNAP-25 product in 
the CNS after peripheral injections in rats (3-5 days), and the long distance from the injection 
site to central regions where toxin’s proteolytic activity was observed, rule out the possibility 
of passive intraneuronal diffusion (Antonucci et al., 2008; Matak et al., 2012).  
44 
 
Studies involving cleaved SNAP-25 detection lacked the direct evidence for toxin traffic via 
axonal transport. Immunohistochemistry of BoNT/A-truncated SNAP-25 in regions distant 
from the injection site provided only the indirect evidence of toxin’s axonal traffic. 
Theoretically, instead of BoNT/A, truncated SNAP-25 could have been transported along 
nerves. Strong in vivo evidence in favor of BoNT/A traffic was provided by experiments 
demonstrating long-term presence of BoNT/A protease in retina after toxin’s application into 
the optic tectum (Antonucci et al., 2008). After tectal injection, toxin’s proteolytic activity was 
detected in retina. The authors then cut the optic nerve to prevent the additional axonal 
transport from toxin-injected tectum. Subsequently, they employed eye intravitreal injection of 
transiently active BoNT/E, which cleaves SNAP-25 at a cleavage site further from C-terminal 
compared to BoNT/A. BoNT/E is therefore able to cleave both intact and BoNT/A-cleaved 
SNAP-25 and convert them to a single population of BoNT/E-cleaved SNAP-25 (Keller and 
Neale, 1999). Intravitreal BoNT/E transiently reduced the immunoreactivity of BoNT/A-
truncated SNAP-25 in retina. Re-appearance of BoNT/A-truncated SNAP-25 upon 
completion of BoNT/E effects demonstrated that the BoNT/A protease itself had been 
axonally transported to the retina. BoNT/A-truncated SNAP-25 re-occurred due to longer 
intracellular duration of proteolytic action of BoNT/A LC in comparison to BoNT/E LC 
(Antonucci et al., 2008; Keller and Neale, 1999). In a similar experiment it was demonstrated 
that BoNT/A protease was anterogradely transported and transcytosed to second-order 
synapses in superior colliculus (Restani et al., 2011). BoNT/A was injected into the retina and 
its proteolytic activity was demonstrated in optic tectum after 3 days. The optic nerve was 
transected to prevent additional axonal transport from retina. Subsequent BoNT/E application 
into the superior colliculus transiently depleted the immunoreactivity of BoNT/A-truncated 
SNAP-25. Re-occurrence of BoNT/A-truncated SNAP-25 after completion of BoNT/E effects 
demonstrated the long-term presence of anterogradely transported BoNT/A.  
Novel studies on the BoNT/A activity in the optic system provided evidence for axonal 
transport and transcytosis to higher order synapses in CNS, with resulting blockage of 
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neurotransmitter release in distant synapses (Restani et al., 2012a). When BoNT/A was 
injected in optic tectum, ultrastructural analysis revealed swelling and accumulation of 
synaptic vesicles inside retinal terminals, indicative of impaired neuroexocytosis (Restani et 
al., 2012a). Additionally, BoNT/A injected into the tectum of rat pups induced an inhibition of 
cholinergic-driven wave activity in retina. This study demonstrated BoNT/A transcytosis from 
retinal ganglion neurons to cholinergic amacrine cells, and subsequent inhibition of 
acetylcholine release (Restani et al., 2012a).   
In addition to the indirect in vivo evidence involving immunodetection of BoNT/A-cleaved 
SNAP-25, axonal transport of BoNTs was recently directly visualized in vitro by examining 
the traffic of Alexa Fluor-fluorescently labeled BoNT/A and BoNT/E within the 
compartmentalized culture of primary motor neurons (Restani et al., 2012b). It was observed 
that both full-length toxins and their heavy chains were internalized into the neuronal non-
acidic vesicles. Vesicles containing toxins were then redirected to the fast retrograde axonal 
transport machinery in the motoneuronal axons (Restani et al., 2012b). The authors 
suggested that BoNT/A and BoNT/E share similar axonal intra-vesicular trafficking pathways 
with different neurotrophic factors, viral pathogens and TeNT.  
 
 
6. 5 Immunohistochemical evidence for axonal transport of enzymatically active 
BoNT/A to central nociceptive regions 
 
Behavioral data involving colchicine and intraneural or intraganglionic BoNT/A injections 
suggested that BoNT/A-mediated antinociceptive activity involves axonal transport of active 
toxin molecule within peripheral sensory neurons, possibly to the CNS (Section 6. 2. 1). 
Evidence that the axonally transported BoNT/A molecules are directed to central sensory 
regions was provided by immunohistochemistry of cleaved SNAP-25. By employing the 
same antibody as Antonucci et al. (2008), central cleaved SNAP-25 was detected in spinal 
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trigeminal nucleus caudalis after toxin injection into the trigeminal area (Figure 3) (Matak et 
al., 2011). Cleaved SNAP-25 in CNS was observed starting from 3 days after toxin peripheral 
injection. BoNT/A-truncated SNAP-25 occurred in trigeminal nucleus caudalis even at 3.5 
U/kg, the lowest peripheral dose able to induce the antinociceptive effect in rats (Bach-
Rojecky and Lacković, 2005; Matak et al., 2011). Similarly, hind-limb injection of BoNT/A 
resulted in cleavage of SNAP-25 in lumbar dorsal horn at low peripheral dose (5 U/kg) 
(Matak et al., 2012), suggesting a long-distance axonal traffic in spinal sensory neurons. 
BoNT/A enzymatic activity in lumbar dorsal horn and trigeminal sensory nuclei indicated that 
BoNT/A may interfere with nociceptive neurotransmission between peripheral and central 
sensory neurons, most likely by preventing the SNARE-mediated vesicular neurotransmitter 
release (Matak et al, 2011).  
In mice, it was reported that BoNT/A-mediated SNAP-25 cleavage is present along the 
nociceptive pathway: in the injected hind-paw skin, along the sciatic nerve, in peripheral 
ganglia and within the spinal cord (Marinelli et al., 2012). Most recent study suggested that 
BoNT/B, applied at high peripheral dose, may also be axonally transported in mouse sensory 
neurons. Marino et al. (2014) reported reduction of VAMP/synaptobrevin immunoreactivity in 
dorsal root ganglia after BoNT/B intraplantar injection in mice, suggesting BoNT/B enzymatic 
activity in the ganglia. In addition, the authors showed reduced neurokinin 1 receptor 
internalization evoked by intraplantar formalin or intrathecal capsaicin, and suggested that 
BoNT/B may reduce spinal substance P presynaptic release (Marino et al., 2014).   
 
Figure 3  
Figure 4 
 
 
7. WHAT IS THE MECHANISM OF BONT/A ANTINOCICEPTIVE ACTION IN CNS? 
POSSIBLE ROLE OF OPIOIDERGIC AND GABA-ERGIC NEUROTRANSMISSION  
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In this review we have discussed the evidence that BoNT/A antinociceptive effect is centrally 
mediated. However, up to now, the mechanism of central antinociceptive action has 
remained unknown. Recently, we have found that it might be connected with opioid and 
GABA-ergic system in the CNS.  
Few experimental studies  demonstrated the synergistic activity of ineffective doses of 
morphine and BoNT/A on inflammatory pain induced by carrageenan and formalin, and 
neuropathic pain evoked by chronic constriction sciatic injury (Auguet et al., 2008; Vacca et 
al., 2012; Vacca et al., 2013). In addition, peripherally applied BoNT/A prevented the 
development of morphine-induced tolerance and associated glial activation in lumbar spinal 
cord (Vacca et al., 2012; Vacca et al., 2013). These studies indirectly suggested that 
BoNT/A’s antinociceptive action might be connected with the endogenous opioid system. In 
our experiments (Drinovac et al., 2013) opioid antagonist naltrexone, injected both 
systemically or intrathecally, dose-dependently prevented the BoNT/A-mediated reduction of 
second phase nocifensive behavior (paw licking and flinching) in a model of formalin-induced 
pain. Effectiveness of low intrathecal dose of naltrexone suggested that the effect is 
mediated at the spinal level. BoNT/A activity was demonstrated to be mediated by the µ-
opioid receptor by selective µ-antagonist naloxonazine. Reduction of dorsal horn c-Fos 
expression by BoNT/A in a model of formalin-induced pain was also prevented by 
naltrexone. Additionally, systemically injected naltrexone prevented the BoNT/A’s effects on 
thermal and mechanical thresholds, as well as cold allodynia in a model of partial nerve 
transection-induced neuropathic pain. These observations suggested that BoNT/A’s 
antinociceptive activity in acute inflammatory and neuropathic pain is associated with the 
enhanced function of endogenous opioid system via central µ-opioid receptors (Drinovac et 
al., 2013).  
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In addition, we examined the possible role of GABA-ergic inhibitory neurotransmission in 
BoNT/A action because of its wide involvement in chronic pain patophysiology (Drinovac et 
al., 2014). The effect of GABA antagonism was similar to opioid antagonists: GABA-A 
antagonist bicuculline prevented the BoNT/A-mediated antinociceptive effect in formalin-
induced inflammatory pain, as well as in sciatic nerve transection-induced neuropathy. 
Intrathecal bicuculline prevented the BoNT/A action similar to systemic bicuculline, while 
intracisternal application had no effect, suggesting that BoNT/A interacts with GABA-ergic 
transmission at the spinal cord level. Enhancement of inhibitory neurotransmission may 
explain BoNT/A efficacy in relieving chronic pain and hypersensitivity (Drinovac et al., 2014). 
BoNT/A effect in CNS, along with proposed inhibition of SNARE-mediated central 
neurotransmitter release (Matak et al., 2011, Matak et al., 2012) (Figure 4), seems to involve 
increased endogenous opioidergic and GABA-ergic transmission (Drinovac et al., 2013; 
Drinovac et al., 2014). These data at first might seem counter-intuitive, since BoNT/A is a 
selective blocker of neurotransmitter release, with preference for excitatory synapses. We 
speculate that BoNT/A-mediated blockage of excitatory synapses might lead indirectly to 
enhanced inhibitory neurotransmission via yet unknown mechanism.  
 
 
8. CONCLUDING OVERVIEW 
 
8. 1. Central vs. peripheral action of BoNT/A 
 
Main arguments for the peripheral site of BoNT/A action on pain are based on its inhibitory 
effects on peripheral glutamate and neuropeptide release, and its presumed analogy to 
widely known BoNT/A anticholinergic effects on peripheral motor nerve endings and 
autonomic synapses (Table 1, left column). Later, this hypothesis was modified with the 
assumption that repeated stimulation, inflammation or nerve injury may sensitize peripheral 
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nerve endings resulting in excess stimulation of CNS leading to central sensitization (Aoki 
and Francis, 2011). Accordingly, BoNT/A “may directly inhibit primary sensory fibers, leading 
to a reduction of peripheral sensitization, and an indirect reduction in central sensitization, 
receptor field expansion, and allodynia” (Aoki and Francis, 2011).  
Evidence for central site of BoNT/A action are based on behavioral studies which reported 
distant BoNT/A effect on bilateral pain of different origins, necessity of axonal transport, 
increased potency after central application and immunohistochemical studies involving 
selective toxin’s enzymatic activity in central sensory nociceptive nuclei after peripheral 
application (Table 1, right column).  
The assumption that BoNT/A has a primary peripheral site of action fails to explain some 
clinical data, too. For example, migraine is by definition a CNS disease and it remains 
unclear why peripherally acting BoNT/A can have a long lasting beneficial effect on it. Few 
reports on the beneficial effect of BoNT/A on phantom pain (Jin et al., 2009; Wu et al 2012) 
additionally indicate the limitations of the peripheral hypothesis.  
Some contradictory experimental data regarding the time-course of onset of BoNT/A action 
and anti-inflammatory activity in different inflammatory pain models is summarized in Table 
2.  
 
Table 1 
Table 2 
 
8. 2. Is there any predictive value of preclinical discoveries about the central 
mechanism of BoNT/A action? 
 
Targeting nerves and ganglia for pain treatment. BoNT/A injected directly into peripheral 
nerves or sensory ganglia has an increased potency and similar efficacy compared to 
peripheral injections in rats (Sections 5. 3 and 6. 2). By employing a procedure similar to 
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classical nerve blocks, Kapural et al. (2007) found that the BoNT/A injection into the 
perineural space of greater occipital nerve reduced the pain associated with occipital 
neuralgia. Thus, BoNT/A perineural use may be an effective alternative for treatment of focal 
neuropathies attributable to a locally damaged nerve branch. Treatment of neuromas and 
nerve stumps in damaged or transected nerves has also been clinically reported, suggesting 
a possible use in dentistry, treatment of phantom limb pain etc (Climent et al., 2013). These 
preclinical and clinical observations suggest that a more proximal (intraneuronal or 
intraganglionic), or even central delivery of low dose BoNT/A may be a useful therapeutic 
strategy for pain treatment. However, these options should be carefully considered before 
proceeding with further clinical research. There are unresolved issues in human and animal 
research regarding the BoNT/A traffic and potential consequences of its action in the CNS 
(Lacković et al., 2009). Experimental data suggests that BoNT/A, following axonal transport, 
may be transcytosed within the CNS and reach second-order or even third-order synapses 
(Restani et al., 2012; Akaike et al., 2012). Since the possible transcytosis and traffic to 
distant regions in the CNS have not been characterized in sensory and motor system of 
animals or humans, their potential clinical relevance and safety issues need to be examined.  
Synergism with analgesics. We reported a connection of BoNT/A action with the endogenous 
opioid system and µ-opioid receptors (Drinovac et al., 2013). Additionally, experimental 
studies suggested that BoNT/A acts synergistically with morphine and may counteract the 
tolerance associated with use of high doses of opioids (Auguet et al., 2008; Vacca et al., 
2012; Vacca et al., 2013). These observations suggest that BoNT/A may be combined with 
low dose morphine and prevent the development of tolerance to opioid analgesics. This is in 
line with clinical observations that BoNT/A is effective in treatment of chronic migraine in 
patients with reported medication overuse (Silberstein et al., 2013). BoNT/A even reduced 
the amount of triptans used in migraine patients (Silberstein et al., 2013). Potential beneficial 
pharmacological interactions of BoNT/A with opioids, but also with other types of drugs need 
to be assessed in the future.  
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Chronic migraine is at the moment the only approved indication for BoNT/A use in pain 
conditions. However, the mechanism of BoNT/A action on migraine is unknown. It was 
hypothesized that BoNT/A may reduce the tension of pericranial muscles and reduce the 
mechanical sensitivity of muscular nociceptors (Gazerani et al., 2010). In contrast to the 
suggested peripheral site of BoNT/A action, it is widely believed that the patophysiologically 
most important cause of migraine pain is the neurogenic vasodilation of dural blood vessels 
(Geppetti et al., 2011). This is supported by clinical effectiveness of antimigraine drugs like 
triptans and CGRP antagonists, which target dural neurogenic vasodilatation (Geppetti et al., 
2011).  
In trigeminal pain models we found that BoNT/A may reduce the neurogenic inflammation in 
dural meninges (Filipović et al., 2012; Matak et al., 2011). Neuropathic and inflammatory pain 
in trigeminal area, evoked by infraorbital nerve constriction and formalin, was shown to be 
accompanied by dural neurogenic inflammation (Filipović et al., 2012; Filipović et al., 2014). 
Single peripheral BoNT/A injection completely resolved the pain-evoked dural plasma protein 
extravasation. Similarly to reduction of allodynia, BoNT/A’s suppressive action on dural 
neurogenic inflammation was found to be mediated by toxin’s axonal transport in trigeminal 
nerve (Filipović et al., 2012). Few studies also reported the action of peripherally applied 
BoNT/A at the level of trigeminal ganglion (Section 4. 5).  
During migraine attack, peripheral sensitization occurs due to activation of trigeminal nerve 
fibers innervating dura mater and blood vessels, leading to throbbing pain (Mathew, 2011). 
Prolonged peripheral sensitization leads to central sensitization of second order trigeminal 
nucleus caudalis neurons, where the extracranial and intracranial inputs converge. This in 
turn induces cutaneous allodynia and scalp hypersensitivity in the pericranial area (Mathew, 
2011). BoNT/A-mediated reduction of neurogenic inflammation suggest that it might be 
active on the level of peripheral dural afferent terminals, thus, preventing intracranial 
peripheral sensitization. In addition, after peripheral delivery BoNT/A may be axonally 
transported to central spinal trigeminal nucleus caudalis (Matak et al., 2011). Cleaved SNAP-
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25 occurrence in TNC suggest that BoNT/A might be active also at the level of second order 
neurons in the TNC, which receive convergent nociceptive input from trigeminal nerve and 
mediate central sensitization (Filipović et al., 2012; Matak et al., 2011). 
Hyperalgesia and allodynia. BoNT/A does not alter normal nociceptive thresholds or acute 
nociceptive pain in humans or animals, as well as immediate painful response to formalin 
injection (phase I). In contrast, there is a long-lasting BoNT/A induced reduction of 
hyperalgesia and allodynia, associated with central sensitization (Section 4.3). It can be 
hypothesized that, in patients, pain (including migraine) associated with hyperalgesia and 
allodynia might be more sensitive to BoNT/A action.  
 
 
8. 3. What we do not know about BoNT/A and CNS 
 
Discovery of axonal transport of BoNT/A to the CNS after peripheral application of very small 
amount raises many new questions about the significance of BoNT/A action in the brain: 
• Clinical significance of axonal transport of BoNT/A in motoneurons is not known. At 
present there is not even a hypothesis about that.  
• Why does BoNT/A act only on some types of pain primarily accompanied with 
hyperalgesia and allodynia? Does BoNT/A act only on the subset of sensory neurons 
or only on some aspects of central neurotransmission? 
• Possible transsynaptic transport of BoNT/A inside the brain after peripheral injection. 
Up to now, such transport is clearly shown only after application of BoNT/A directly to 
some brain areas (including retina).  
• The mechanism of BoNT/A bilateral effect in mirror and polyneuropathic pain models 
remains unknown.  
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• After BoNT/A application in the craniocervical region, BoNT/A might be axonally 
transported to brainstem/cervical sensory and motor regions, depending on the 
innervation of injected sites. After it reaches sensory or motor regions, the 
metabolism of BoNT/A in the CNS remains unclear.    
• In neuromuscular junction, BoNT/A induces denervation accompanied by sprouting of 
new synapses (Duchen et al., 1975; reviewed by Meunier et al., 2002; Wright et al., 
2007). On the contrary, in neuronal cultures BoNT/A prevents SNAP-25-mediated 
axonal and dendritic outgrowth (Grosse et al., 1999; Morihara et al., 1999). It is not 
known whether similar BoNT/A-induced morphological changes occur in the brain in 
vivo. Beyond BoNT/A pharmacology, those issues might be important since synaptic 
plasticity is suggested to be the underlying mechanism of chronic pain, phantom pain, 
etc.  
• The role of SNAP-25 away from classical synapses along the axons or dendrites is 
not clear. Accordingly, potential significance of BoNT/A effects outside of synaptic 
zones in vivo needs to be further characterized.  
• Are there any additional targets/mechanisms of BoNT/A action in the CNS, not 
necessarily connected with SNAP-25-mediated release of neurotransmitters? 
 
9. CONCLUSION 
 
The dominant opinion suggests that the inhibition of peripheral neurotransmitter 
/inflammatory mediator release is the underlying primary mechanism of BoNT/A’s 
antinociceptive action. A modification of this opinion includes the secondary effects on 
central sensitization. However, a literature overview presented here suggests that the 
existing experimental and clinical data on BoNT/A antinociceptive action cannot be 
adequately explained by this hypothesis. Several reports demonstrated that BoNT/A induces 
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bilateral effects after unilateral injection in mirror or polyneuropathic pain of different origins. 
In addition, the antinociceptive effect of peripherally applied BoNT/A is shown to be 
dependent on axonal transport in sensory nerves. Enzymatic activity of BoNT/A can be 
immunohistochemically visualized in the spinal cord or brainstem areas receiving sensory 
input from the toxin’s peripheral injection site. Additionally, BoNT/A’s antinociceptive activity 
is shown to be associated with central µ-opioid and GABA-A receptors. The discovery that 
the BoNT/A action on pain is dominantly a central effect raises many new questions requiring 
additional research concerning the mechanisms of toxin action in CNS. Elucidation of 
antinociceptive mechanisms would be invaluable for further development of BoNT/A use in 
pain, and possibly some other clinical indications. In addition, it might contribute to better 
understanding of chronic pain pathophysiology.  
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Figure 1 Schematic representation of of 150 kDa BoNT/A neurotoxin molecule consisting of 
light chain (50 kDa, Zn-endopeptidase, dark red) coupled with heavy chain (100 kDa, light 
red) by sulphur bridge. S, sulphur; Zn, zinc. Accessory proteins of 750 kDa comprising the 
rest of 900 kDa complex are not shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
Figure 2 Mechanism of botulinum toxin type A (BoNT/A)-mediated prevention of 
neurotransmitter release 
Left: 
Schematic representation of 150 kDa BoNT/A neurotoxin (red) consisting of heavy chain and 
light chain coupled with disulphide bonds (yellow). Light chain contains zinc ion (green).  
BoNT/A heavy chain recognizes the dual ganglioside-protein acceptors (grey oval shape) on 
the outer side of plasma membrane and it is internalized into synaptic vesicles. BoNT/A LC is 
then translocated into the cytosol.  
Right:  
Light-chain cleaves membrane-associated synaptosomal-associated protein of 25 kDa 
(SNAP-25) which prevents vesicle fusion with membrane. This induces prevention of 
neurotransmitter release and build-up of synaptic vesicles in the synapse.  
100, 100 kDa BoNT/A heavy chain; 50, 50 kDa BoNT/A light chain; SNAP-25; synaptosomal-
associated protein of 25 kDa (black rectangle); light green rectangle represents syntaxin, 
brown rectangle represents vesicle associated membrane protein/synaptobrevin, blue 
pentamer represents postsynaptic neurotransmitter receptor; red pentagon represents 
neurotransmitter. Size of of schematic representations of proteins, atoms and 
neurotransmitter is not shown in scale compared to synaptic structures and vesicles.  
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Figure 3. Fluorescent microphotograph of cleaved SNAP-25 in the ipsilateral trigeminal 
nucleus caudalis 5 d after BoNT/A (15 U/kg) injection into the rat whisker pad. 
Immunohistochemical procedure is previously published (Matak et al., 2011). Red 
fluorescent signal represents cleaved SNAP-25, while blue fluorescence represents nuclear 
counterstaining with diamidino-2-phenylindole (DAPI). Lateral edge of brainstem section is 
visible in the upper right corner. Scale bar = 100 µm  
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Figure 4 Suggested mechanism of BoNT/A analgesic activity on the level of central sensory 
afferent terminals. 
A.) Neurotransmission of lasting inflammatory and chronic pain. Painful signal from the 
stimulated peripheral nerve endings (red) is transmitted along pseudounipolar sensory 
neuron to the spinal cord dorsal horn central afferent terminals (intensive red), where it 
induces central sensitization, leading to hyperalgesic responses. 
 B.) By entering sensory neurons and axonal transport to the dorsal horn, followed by 
subsequent central SNAP-25 cleavage, BoNT/A prevents nociceptive neurotransmitter 
release from central afferent terminals. Different color (grey vs red) indicates possible 
change in neuronal activity. 
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Table 1 Systemic reviews and meta-analyses of BoNT/A efficacy in treatment of pain 
disorders.  
 
Clinical 
condition 
N (trials 
included) 
N (patients 
included) 
Outcome 
 
reference 
Myofascial pain 
syndromes 
4 233 Inconclusive 
evidence for 
effectiveness 
Soares et 
al., 2012 
Subacute/chronic 
neck pain. 
9 503 Lack of benefit Langevin et 
al., 2011 
low-back pain 
and sciatica 
3 123 Low-quality 
evidence that 
BoNT/A is 
beneficial 
Waseem et 
al., 2011 
Shoulder pain 
due to spastic 
hemiplegia or 
arthritis 
6 164 BoNT/A 
reduces pain 
and improves 
shoulder 
function  
Singh and 
Fitzgerald 
(2011) 
Postoperative 
pain after 
subpectoral 
breast implants 
7 427 Low-quality 
evidence that 
BoNT/A is 
beneficial 
Winocour et 
al., 2014 
Trigeminal 
neuralgia 
6 101 BoNT/A may 
be beneficial 
in treatment of 
TN 
Hu et al., 
(2013) 
Tension-type 
headache 
7 675 No reduction 
in the number 
of headaches 
in comparison 
to placebo 
(Jackson et 
al., 2012) 
Episodic 
migraine 
9 1838 No reduction 
in the number 
of headaches 
in comparison 
to placebo 
(Jackson et 
al., 2012) 
118 
 
Chronic migraine 5 1508 Significant 
reduction in 
the number of 
headaches in 
comparison to 
placebo 
(Jackson et 
al., 2012) 
Chronic daily 
headache 
3 1115 Significant 
reduction in 
the number of 
headaches in 
comparison to 
placebo 
(Jackson et 
al., 2012) 
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Table 2 Summary of experimental data supporting peripheral hypothesis of BoNT/A action on 
pain (left) and experimental data supporting central antionociceptive activity of BoNT/A.  
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Table 3 Contradictory experimental data favoring either peripheral or central site of BoNT/A 
action (left vs. right). 
 
 
 
 
 
